Datasets:

xpertsystems
/

hlt003-sample

+---
+license: cc-by-nc-4.0
+task_categories:
+- tabular-classification
+- tabular-regression
+- time-series-forecasting
+language:
+- en
+tags:
+- synthetic
+- healthcare
+- clinical-trials
+- rct
+- randomized-controlled-trial
+- phase-iii
+- phase-ii
+- biostatistics
+- pharma
+- drug-development
+- power-analysis
+- sample-size
+- treatment-effect
+- adverse-events
+- ctcae
+- ich-e9
+- consort
+- cohens-d
+- hazard-ratio
+- odds-ratio
+- progression-free-survival
+- arps
+- itt-population
+- pp-population
+- dropout-modeling
+- mar-mnar
+- biomarker-interaction
+- simulation
+pretty_name: HLT-003 Synthetic Clinical Trial Dataset — 3 Endpoint Types + Power Sweep (Sample Preview)
+size_categories:
+- 1K<n<10K
+---
+# HLT-003 — Synthetic Clinical Trial Dataset (Sample Preview)
+**A free, schema-identical preview of the full HLT-003 commercial product from [XpertSystems.ai](https://xpertsystems.ai).**
+A **fully synthetic** parametric clinical trial simulator demonstrating all three primary endpoint types (CONTINUOUS, BINARY, TTE) plus a sample-size power sweep. Built on JSON-configurable trial designs with ICH E9 / CONSORT 2010 / CTCAE v5.0 conventions for randomization, blinding, dropout modeling, and adverse event reporting.
+> ⚠️ **PRIVACY & SYNTHETIC NATURE**
+> Every record in this dataset is **100% synthetic**. **No real trial participant data, no PHI, no re-identifiable records.** Trial parameters (effect sizes, response rates, dropout rates, AE profiles) match published clinical trial design conventions but the participants are computationally generated.
+---
+## What's in this sample
+### Three sample trials — one per endpoint type
+| File | Trial | Phase | Endpoint | Arms | N | Size |
+|---|---|---|---|---|---|---|
+| `cardiology_ldl_trial.csv` | LDL-C reduction (lipid-lowering therapy) | III | CONTINUOUS | 3 | 800 | 117 KB |
+| `rheumatology_acr20_trial.csv` | ACR20 response (rheumatoid arthritis biologic) | III | BINARY | 3 | 800 | 109 KB |
+| `oncology_pfs_trial.csv` | Progression-free survival (targeted oncology) | II | TTE | 2 | 600 | 80 KB |
+### Configuration templates
+| File | Description |
+|---|---|
+| `cardiology_ldl_config.json` | Full JSON config for the cardiology trial |
+| `rheumatology_acr20_config.json` | Full JSON config for the rheumatology trial |
+| `oncology_pfs_config.json` | Full JSON config for the oncology trial |
+| `trial_config_schema.json` | Complete config API documentation |
+### Power analysis
+| File | Description |
+|---|---|
+| `power_sweep_results.csv` | Power curve at 7 sample sizes (200-2500) × 50 simulations per n, small effect (d=0.10) |
+### Documentation
+| File | Description |
+|---|---|
+| `simulation_audit_log.txt` | Reproducibility audit log from latest trial run |
+| `validation_scorecard.json` | Wrapper-authored 10-metric scorecard with sources |
+**Total:** ~348 KB across 10 files.
+---
+## Schema (all 3 trial CSVs share the same 28-column schema)
+### Trial & participant identity
+`participant_id`, `trial_id`, `therapeutic_area`, `trial_phase`, `arm_id`, `arm_label`, `treatment_effect_d`
+### Demographics
+`age`, `sex`, `bmi`, `disease_severity_score`, `severity_tertile` (Low/Moderate/High), `biomarker_positive`, `elderly_flag`
+### Analysis populations (ICH E9)
+`ITT_flag` (Intent-to-Treat), `PP_flag` (Per-Protocol), `dropout_flag`
+### Endpoint fields (only the trial's endpoint type is populated; others are NaN)
+**CONTINUOUS:** `baseline_ep`, `primary_ep_w24`, `primary_cfb_w24`
+**BINARY:** `binary_response_w24`
+**TTE:** `tte_event_week`, `tte_event_flag`, `tte_censored_flag`
+### Safety (CTCAE v5.0)
+`ae_total_count`, `ae_grade3plus_count`, `ae_sae_count`, `ae_any_flag`
+---
+## Coverage
+**3 endpoint types** — CONTINUOUS (mean change from baseline), BINARY (response rate with odds ratios), TTE (time-to-event with hazard ratios)
+**Therapeutic areas demonstrated** — Cardiology, Rheumatology, Oncology (full product supports 12 areas including Neurology, Metabolic, Respiratory, Psychiatry, Infectious Disease, Rare Disease, Ophthalmology, Dermatology, GI)
+**4 trial phases supported** — I, II, III, IV
+**3 blinding modes** — OPEN, SINGLE, DOUBLE
+**4 randomization schemes** — SIMPLE, BLOCK, STRATIFIED, MINIMIZATION
+**3 dropout mechanisms** — MCAR (Missing Completely At Random), MAR (Missing At Random, logit model with severity/age/arm coefficients), MNAR (Missing Not At Random fraction)
+**5 AE severity grades** — CTCAE v5.0 Grade 1 (mild) through Grade 5 (death)
+**Biomarker × treatment interaction modeling** — predictive biomarker positive fraction with arm-specific effect modification
+**Subgroup effects** — elderly (≥65) AE multipliers, severity tertile stratification
+---
+## Calibration source story
+The full HLT-003 generator is grounded in industry-standard clinical trial methodology:
+- **ICH E9 (1998)** — Statistical Principles for Clinical Trials (ITT/PP analysis populations, primary endpoint analysis conventions)
+- **CONSORT 2010** — Reporting standards for randomized trials
+- **Cohen (1988)** — Statistical Power Analysis (effect size conventions)
+- **ICH E6(R2)** — Good Clinical Practice (randomization, blinding standards)
+- **CTCAE v5.0 (NCI)** — Common Terminology Criteria for Adverse Events
+- **Felson et al. (1995)** — ACR Response Criteria (rheumatoid arthritis)
+- **Cox (1972)** — Proportional hazards model (TTE analysis)
+- **Kaplan-Meier (1958)** — Survival analysis conventions
+- **Cholesterol Treatment Trialists' Collaboration** — LDL-C reduction baselines for statin trials
+### Sample-scale validation scorecard
+| Metric | Observed | Target | Tolerance | Status | Source |
+|---|---|---|---|---|---|
+| CONTINUOUS placebo CFB calibration | -6.78 | -8.0 | ±2.0 | ✅ PASS | CTT Collaboration |
+| CONTINUOUS treatment effect separation | 16.94 | 16.0 | ±4.0 | ✅ PASS | Cohen (1988) |
+| BINARY placebo response rate | 21.1% | 22% | ±6% | ✅ PASS | Felson et al. (1995) |
+| BINARY high-dose response rate | 58.3% | 53% | ±10% | ✅ PASS | Felson et al. (1995) |
+| TTE event rate separation | 6.3% | 10% | ±8% | ✅ PASS | Cox (1972) |
+| Overall dropout rate | 8.9% | 10% | ±6% | ✅ PASS | ICH E9 |
+| AE grade distribution validity | 100% | 100% | ±5% | ✅ PASS | CTCAE v5.0 |
+| ITT population completeness | 100% | 100% | — | ✅ PASS | ICH E9 |
+| Randomization balance | 99.7% | ≥95% | ±5% | ✅ PASS | ICH E6(R2) GCP |
+| Endpoint field type compliance | 100% | 100% | — | ✅ PASS | Data hygiene invariant |
+**Grade: A+ (100/100) — verified across 6 random seeds (42, 7, 123, 2024, 99, 1).**
+### Power curve (small effect d=0.10, 2-arm continuous)
+```
+n=200   →  power = 0.28
+n=400   →  power = 0.58
+n=600   →  power = 0.70
+n=800   →  power = 0.74
+n=1200  →  power = 0.92   ← crosses 80% threshold
+n=1800  →  power = 1.00
+n=2500  →  power = 1.00
+```
+Classic S-shaped power curve — the kind of output biostatisticians use for trial sample-size justification.
+---
+## Loading examples
+### Pandas — explore the 3 trials
+```python
+import pandas as pd
+cont = pd.read_csv("cardiology_ldl_trial.csv")
+binr = pd.read_csv("rheumatology_acr20_trial.csv")
+tte = pd.read_csv("oncology_pfs_trial.csv")
+print("CONTINUOUS trial — mean change from baseline by arm:")
+print(cont.groupby("arm_label")["primary_cfb_w24"].agg(["mean", "std", "count"]))
+print("\nBINARY trial — response rates by arm:")
+print(binr.groupby("arm_label")["binary_response_w24"].mean())
+print("\nTTE trial — event vs censored by arm:")
+print(tte.groupby("arm_label")[["tte_event_flag", "tte_censored_flag"]].sum())
+```
+### Hugging Face Datasets
+```python
+from datasets import load_dataset
+ds = load_dataset("xpertsystems/hlt003-sample", data_files={
+    "continuous": "cardiology_ldl_trial.csv",
+    "binary":     "rheumatology_acr20_trial.csv",
+    "tte":        "oncology_pfs_trial.csv",
+    "power":      "power_sweep_results.csv",
+})
+print(ds)
+```
+### Reproducing a primary analysis (CONTINUOUS endpoint)
+```python
+import pandas as pd
+from scipy import stats
+df = pd.read_csv("cardiology_ldl_trial.csv")
+itt = df[df["ITT_flag"] == 1]
+arm_placebo = itt[itt["arm_id"] == 0]["primary_cfb_w24"].dropna()
+arm_high    = itt[itt["arm_id"] == 2]["primary_cfb_w24"].dropna()
+t, p = stats.ttest_ind(arm_placebo, arm_high)
+print(f"Placebo CFB mean: {arm_placebo.mean():.2f} mg/dL (n={len(arm_placebo)})")
+print(f"100mg CFB mean:   {arm_high.mean():.2f} mg/dL (n={len(arm_high)})")
+print(f"Treatment effect: {arm_high.mean() - arm_placebo.mean():.2f} mg/dL")
+print(f"t={t:.2f}, p={p:.4g}")
+```
+### Reproducing a Kaplan-Meier curve (TTE endpoint)
+```python
+import pandas as pd
+import matplotlib.pyplot as plt
+# Optional: pip install lifelines for proper KM curves
+from lifelines import KaplanMeierFitter
+df = pd.read_csv("oncology_pfs_trial.csv")
+fig, ax = plt.subplots(figsize=(8, 5))
+for arm_id, arm_df in df.groupby("arm_id"):
+    kmf = KaplanMeierFitter()
+    kmf.fit(arm_df["tte_event_week"], event_observed=arm_df["tte_event_flag"],
+            label=arm_df["arm_label"].iloc[0])
+    kmf.plot_survival_function(ax=ax)
+ax.set_xlabel("Weeks"); ax.set_ylabel("Progression-Free Survival")
+plt.show()
+```
+### Using a JSON config to design your own trial
+```python
+import json
+# Load one of the included configs as a starting point
+with open("cardiology_ldl_config.json") as f:
+    config = json.load(f)
+# Modify for your trial design
+config["trial_id"] = "MY-TRIAL-001"
+config["n_participants"] = 1500
+config["arms"][1]["treatment_effect_cohens_d"] = 0.55  # smaller effect
+config["dropout_mcar_rate"] = 0.08  # higher base dropout
+with open("my_custom_trial.json", "w") as f:
+    json.dump(config, f, indent=2)
+# Then run the full HLT-003 generator:
+#   python hlt003_simulation_engine.py --config my_custom_trial.json
+```
+---
+## Suggested use cases
+- **Power analysis & sample-size calculation** — reproduce the included power sweep with custom effect sizes, validate analytical power formulas (e.g. Cohen's `pwr` package) against Monte Carlo simulation
+- **Statistical test selection** — practice choosing t-test / Wilcoxon / chi-square / Fisher / log-rank / Cox on the appropriate endpoint type
+- **Missing data methodology** — develop and test MAR/MNAR imputation strategies on the dropout-flagged data
+- **ITT vs PP comparison** — quantify the bias from per-protocol analysis vs intent-to-treat
+- **Biomarker subgroup analysis** — test prespecified subgroup hypotheses on `biomarker_positive`
+- **Adverse event signal detection** — train classifiers on `ae_grade3plus_count` and `ae_sae_count` against arm/severity features
+- **Survival analysis** — fit Kaplan-Meier, Cox proportional hazards, accelerated failure time models on the TTE trial
+- **Trial design optimization** — compare 2-arm vs 3-arm designs, dose-ranging vs head-to-head, fixed vs adaptive randomization
+- **Educational use** — biostatistics coursework demonstrating endpoint types, randomization, dropout, AE reporting
+- **Pharma data pipeline testing** — validate ETL pipelines, SDTM/ADaM converters, e-CRF systems against schema-compliant synthetic data
+---
+## Sample vs. full product
+| Aspect | This sample | Full HLT-003 product |
+|---|---|---|
+| Trials demonstrated | 3 (one per endpoint type) | Unlimited via JSON config |
+| Patients per trial | 600-800 | Up to 50,000 |
+| Power sweep | 7 n values × 50 sims | 9+ n values × 200 sims + matplotlib chart |
+| Therapeutic areas | 3 (Cardio, Rheum, Onc) | All 12 (incl. Neuro, Metabolic, Resp, Psych, ID, Rare, Ophth, Derm, GI) |
+| Phases | II, III | I, II, III, IV |
+| Schema | identical | identical |
+| Config API | identical | identical |
+| License | CC-BY-NC-4.0 | Commercial license |
+The full product unlocks unlimited custom trial configurations, larger participant counts for adaptive-design simulations, full power-sweep chart output, and commercial use. **Contact us for the full product.**
+---
+## Limitations & honest disclosures
+- **Sample is preview-only.** 3 trials × 600-800 patients is enough to demonstrate the JSON config API, endpoint types, and validation scorecard, but is **not statistically sufficient** for serious drug development simulation work. The full product supports up to 50K patients per trial.
+- **`treatment_effect_cohens_d` is a generator parameter, not the textbook post-trial Cohen's d.** The generator uses it as a multiplier in its CFB formula (`active_bonus = -|placebo_cfb| × d × 2.5`); the actual post-trial Cohen's d for the comparison depends on the residual SD. For example, the cardiology config's d=0.75 produces an actual post-trial Cohen's d of ~1.5 (Δ=15 vs σ_residual=10.5). Use the power sweep (which simulates the actual statistical test) for true power calculations.
+- **Power sweep uses only 50 simulations per n.** Production-grade power analyses use 1,000-10,000 sims per n. The included sweep is a demonstration; the full product runs 200+ sims by default with optional escalation.
+- **No matplotlib chart in the sample.** The full product generates a PNG power curve chart with 80%/90% threshold lines and the minimum-n-for-80%-power annotation. Excluded from this preview for HF size hygiene.
+- **Single-visit endpoint** (no repeated measures). Each participant has one CFB value at "week 24" — no per-visit longitudinal endpoint trajectories. The full product can be extended with visit-level repeated measures.
+- **Synthetic, not derived from real trial data.** Effect sizes, dropout patterns, and AE profiles follow published clinical trial conventions but do NOT reflect any specific real trial. Use synthetic data for design, methodology development, and ETL testing; validate final designs against published trial literature and prior real trials.
+- **No FDA SDTM/ADaM CDISC compliance in the sample CSVs.** The wide-format CSV is a flat preview format, not CDISC-conformant DM/AE/LB/QS domain tables. CDISC mapping is available in the full product (contact for SDTM/ADaM ETL).
+- **Endpoint-type field hygiene is enforced**: only the trial's endpoint type populates its fields; other endpoint fields are NaN. This is by design (data hygiene invariant) and is validated as one of the 10 scorecard metrics.
+- **No multi-region pooling complexity.** The sample treats sites as independent; the full product supports multi-region trial design with region-specific stratification.
+---
+## Ethical use guidance
+This dataset is designed for:
+- Biostatistics method development and educational use
+- Trial design simulation and power analysis
+- ETL pipeline testing against schema-compliant synthetic data
+- Pharma data engineering and validation
+This dataset is **not appropriate for**:
+- Submission as evidence for regulatory filings (use real trial data)
+- Drug efficacy claims of any kind
+- Predicting outcomes for any specific real intervention
+- Training models that produce clinical recommendations
+---
+## Companion datasets in the Healthcare vertical
+- [HLT-001](https://huggingface.co/datasets/xpertsystems/hlt001-sample) — Synthetic Patient Population (5K patients × 79 cols, CDC/NHANES calibrated)
+- [HLT-002](https://huggingface.co/datasets/xpertsystems/hlt002-sample) — Synthetic EHR Dataset (4K encounters + FHIR R4 bundles, HL7/ICD-10/RxNorm/LOINC)
+- **HLT-003** — Synthetic Clinical Trial Dataset (you are here)
+Use **HLT-001 + HLT-002 + HLT-003 together** for full population-to-encounter-to-trial healthcare ML workflows.
+---
+## Citation
+If you use this dataset, please cite:
+```bibtex
+@dataset{xpertsystems_hlt003_sample_2026,
+  author       = {XpertSystems.ai},
+  title        = {HLT-003 Synthetic Clinical Trial Dataset (Sample Preview)},
+  year         = 2026,
+  publisher    = {Hugging Face},
+  url          = {https://huggingface.co/datasets/xpertsystems/hlt003-sample}
+}
+```
+---
+## Contact
+- **Web:** [https://xpertsystems.ai](https://xpertsystems.ai)
+- **Email:** [pradeep@xpertsystems.ai](mailto:pradeep@xpertsystems.ai)
+- **Full product catalog:** Cybersecurity, Insurance & Risk, Materials & Energy, Oil & Gas, Healthcare, and more
+**Sample License:** CC-BY-NC-4.0 (Creative Commons Attribution-NonCommercial 4.0)
+**Full product License:** Commercial — please contact for pricing.

cardiology_ldl_config.json ADDED Viewed

	@@ -0,0 +1,84 @@

+{
+  "trial_id": "HLT003-CARD-CONT-001",
+  "trial_name": "Phase III RCT \u2014 LDL-C Reduction with Lipid-Lowering Therapy",
+  "sponsor": "XpertSystems Pharma LLC",
+  "n_participants": 800,
+  "trial_phase": "III",
+  "blinding": "DOUBLE",
+  "randomization": "STRATIFIED",
+  "n_sites": 30,
+  "arms": [
+    {
+      "arm_id": 0,
+      "label": "Placebo",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.0,
+      "ae_multiplier": 1.0
+    },
+    {
+      "arm_id": 1,
+      "label": "Drug A 50mg",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.4,
+      "ae_multiplier": 1.6
+    },
+    {
+      "arm_id": 2,
+      "label": "Drug A 100mg",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.75,
+      "ae_multiplier": 2.2
+    }
+  ],
+  "therapeutic_area": "Cardiology",
+  "endpoint_type": "CONTINUOUS",
+  "endpoint_name": "LDL-C Reduction (mg/dL)",
+  "endpoint_unit": "mg/dL",
+  "baseline_mean": 148.0,
+  "baseline_sd": 30.0,
+  "placebo_change_mean": -8.0,
+  "residual_sd_factor": 0.35,
+  "visit_schedule": [
+    -2,
+    0,
+    1,
+    2,
+    4,
+    8,
+    12,
+    16,
+    20,
+    24,
+    28
+  ],
+  "dropout_mcar_rate": 0.04,
+  "dropout_mar_baseline_logit": -3.5,
+  "dropout_mar_severity_coef": 0.025,
+  "dropout_mar_age_coef": 0.015,
+  "dropout_mar_arm_coef": 0.4,
+  "dropout_mnar_fraction": 0.15,
+  "ae_base_rate_per_patient": 3.2,
+  "ae_active_arm_increment": 1.5,
+  "ae_grade_probs_placebo": [
+    0.45,
+    0.32,
+    0.16,
+    0.05,
+    0.02
+  ],
+  "ae_grade_probs_active": [
+    0.38,
+    0.3,
+    0.2,
+    0.08,
+    0.04
+  ],
+  "subgroups": {
+    "biomarker_positive_fraction": 0.42,
+    "biomarker_treatment_interaction": 0.2,
+    "elderly_fraction": 0.28,
+    "elderly_ae_multiplier": 1.3
+  },
+  "output_filename": "cardiology_ldl_trial.csv",
+  "seed": 42
+}

cardiology_ldl_trial.csv ADDED Viewed

The diff for this file is too large to render. See raw diff

oncology_pfs_config.json ADDED Viewed

	@@ -0,0 +1,80 @@

+{
+  "trial_id": "HLT003-ONC-TTE-001",
+  "trial_name": "Phase II RCT \u2014 Oncology Progression-Free Survival",
+  "sponsor": "XpertSystems Pharma LLC",
+  "n_participants": 600,
+  "trial_phase": "II",
+  "blinding": "OPEN",
+  "randomization": "STRATIFIED",
+  "n_sites": 20,
+  "arms": [
+    {
+      "arm_id": 0,
+      "label": "SoC Chemotherapy",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.0,
+      "ae_multiplier": 1.0
+    },
+    {
+      "arm_id": 1,
+      "label": "Targeted Therapy",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.3,
+      "ae_multiplier": 1.3
+    }
+  ],
+  "therapeutic_area": "Oncology",
+  "endpoint_type": "TTE",
+  "endpoint_name": "Progression-Free Survival",
+  "endpoint_unit": "weeks",
+  "tte_median_placebo_weeks": 14.0,
+  "tte_hazard_ratios": [
+    1.0,
+    0.6
+  ],
+  "tte_censoring_rate": 0.35,
+  "treatment_weeks": 52,
+  "visit_schedule": [
+    -2,
+    0,
+    4,
+    8,
+    12,
+    16,
+    20,
+    24,
+    32,
+    40,
+    52
+  ],
+  "dropout_mcar_rate": 0.04,
+  "dropout_mar_baseline_logit": -3.5,
+  "dropout_mar_severity_coef": 0.025,
+  "dropout_mar_age_coef": 0.015,
+  "dropout_mar_arm_coef": 0.4,
+  "dropout_mnar_fraction": 0.15,
+  "ae_base_rate_per_patient": 4.5,
+  "ae_active_arm_increment": 1.5,
+  "ae_grade_probs_placebo": [
+    0.3,
+    0.3,
+    0.25,
+    0.1,
+    0.05
+  ],
+  "ae_grade_probs_active": [
+    0.25,
+    0.28,
+    0.27,
+    0.12,
+    0.08
+  ],
+  "subgroups": {
+    "biomarker_positive_fraction": 0.35,
+    "biomarker_treatment_interaction": 0.25,
+    "elderly_fraction": 0.45,
+    "elderly_ae_multiplier": 1.4
+  },
+  "output_filename": "oncology_pfs_trial.csv",
+  "seed": 42
+}

oncology_pfs_trial.csv ADDED Viewed

	@@ -0,0 +1,601 @@

+participant_id,trial_id,therapeutic_area,trial_phase,arm_id,arm_label,treatment_effect_d,age,sex,bmi,disease_severity_score,severity_tertile,biomarker_positive,elderly_flag,ITT_flag,PP_flag,dropout_flag,baseline_ep,primary_ep_w24,primary_cfb_w24,binary_response_w24,tte_event_week,tte_event_flag,tte_censored_flag,ae_total_count,ae_grade3plus_count,ae_sae_count,ae_any_flag
+HLT003-ONC-TTE-001-00001,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Male,34.4,52.5,Moderate,0,0,1,1,0,,,,,9.17,0,1,6,3,1,1
+HLT003-ONC-TTE-001-00002,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,44,Female,18.9,82.6,High,0,0,1,1,0,,,,,15.7,1,0,5,2,1,1
+HLT003-ONC-TTE-001-00003,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Male,28.5,73.1,High,1,1,1,1,0,,,,,42.19,1,0,4,1,0,1
+HLT003-ONC-TTE-001-00004,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,68,Female,30.1,50.4,Moderate,1,1,1,1,0,,,,,21.07,0,1,19,9,6,1
+HLT003-ONC-TTE-001-00005,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,33,Female,26.8,68.5,High,0,0,1,1,0,,,,,3.19,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00006,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,41,Female,17.8,89.8,High,0,0,1,1,0,,,,,15.26,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00007,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Female,26.6,90.3,High,0,0,1,1,0,,,,,16.2,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00008,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,26.6,32.9,Low,1,0,1,0,0,,,,,21.02,1,0,3,1,0,1
+HLT003-ONC-TTE-001-00009,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,56,Male,27.6,38.3,Low,0,0,1,1,0,,,,,0.39,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00010,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,46,Male,25.2,81.7,High,0,0,1,1,0,,,,,7.84,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00011,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Male,25.9,36.0,Low,0,1,1,1,0,,,,,4.58,1,0,7,5,4,1
+HLT003-ONC-TTE-001-00012,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Female,28.3,31.2,Low,0,1,1,1,0,,,,,18.25,1,0,20,3,1,1
+HLT003-ONC-TTE-001-00013,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,57,Female,31.1,46.2,Moderate,0,0,1,0,1,,,,,6.83,1,0,20,10,7,1
+HLT003-ONC-TTE-001-00014,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Female,26.7,62.6,High,0,1,1,0,1,,,,,4.69,0,1,20,11,6,1
+HLT003-ONC-TTE-001-00015,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,26.1,53.2,Moderate,0,0,1,1,0,,,,,9.97,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00016,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,46,Female,29.0,43.3,Low,0,0,1,0,1,,,,,30.05,1,0,9,4,3,1
+HLT003-ONC-TTE-001-00017,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Female,17.4,42.9,Low,0,0,1,1,0,,,,,11.59,1,0,3,1,0,1
+HLT003-ONC-TTE-001-00018,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,45,Male,31.3,42.2,Low,0,0,1,1,0,,,,,9.41,1,0,6,3,1,1
+HLT003-ONC-TTE-001-00019,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,67,Male,28.5,39.2,Low,1,1,1,1,0,,,,,52.0,0,1,3,1,0,1
+HLT003-ONC-TTE-001-00020,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,56,Female,28.7,96.1,High,1,0,1,1,0,,,,,52.0,0,1,15,10,7,1
+HLT003-ONC-TTE-001-00021,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,54,Female,34.1,60.4,Moderate,0,0,1,1,0,,,,,52.0,0,1,20,5,4,1
+HLT003-ONC-TTE-001-00022,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Male,17.2,71.0,High,0,0,1,0,0,,,,,15.96,0,1,4,1,0,1
+HLT003-ONC-TTE-001-00023,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,71,Male,17.1,46.2,Moderate,0,1,1,1,0,,,,,18.8,0,1,5,2,0,1
+HLT003-ONC-TTE-001-00024,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,30.1,51.7,Moderate,1,0,1,1,0,,,,,33.16,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00025,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Male,28.5,42.2,Low,0,0,1,1,0,,,,,19.76,0,1,5,1,1,1
+HLT003-ONC-TTE-001-00026,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Male,29.5,10.0,Low,1,0,1,1,0,,,,,21.32,1,0,16,7,4,1
+HLT003-ONC-TTE-001-00027,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,63,Female,25.8,30.2,Low,0,0,1,1,0,,,,,25.06,0,1,3,0,0,1
+HLT003-ONC-TTE-001-00028,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Female,32.4,22.4,Low,0,0,1,1,0,,,,,5.31,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00029,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Male,33.9,14.5,Low,0,0,1,1,0,,,,,32.57,1,0,5,4,2,1
+HLT003-ONC-TTE-001-00030,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Female,31.3,33.5,Low,0,0,1,1,0,,,,,7.51,1,0,11,2,1,1
+HLT003-ONC-TTE-001-00031,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,82,Male,27.0,78.8,High,1,1,1,1,0,,,,,29.31,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00032,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Female,16.3,54.2,Moderate,0,0,1,1,0,,,,,2.13,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00033,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Male,33.0,78.2,High,0,0,1,1,0,,,,,2.22,1,0,12,4,0,1
+HLT003-ONC-TTE-001-00034,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,47,Female,35.6,62.4,High,0,0,1,1,0,,,,,2.84,0,1,5,3,0,1
+HLT003-ONC-TTE-001-00035,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,64,Male,32.2,69.1,High,0,0,1,1,0,,,,,33.49,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00036,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Male,23.4,38.8,Low,0,1,1,1,0,,,,,8.78,1,0,10,5,1,1
+HLT003-ONC-TTE-001-00037,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,32.4,64.4,High,1,0,1,1,0,,,,,3.29,1,0,11,2,2,1
+HLT003-ONC-TTE-001-00038,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,33.5,68.1,High,1,0,1,1,0,,,,,34.58,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00039,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,47,Male,37.5,44.6,Low,1,0,1,1,0,,,,,9.46,1,0,3,3,2,1
+HLT003-ONC-TTE-001-00040,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,64,Male,23.4,65.1,High,0,0,1,1,0,,,,,52.0,0,1,20,9,5,1
+HLT003-ONC-TTE-001-00041,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,65,Female,27.2,65.2,High,0,1,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00042,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,63,Female,32.8,45.1,Low,0,0,1,1,0,,,,,30.8,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00043,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,49,Female,28.8,34.8,Low,1,0,1,0,1,,,,,31.24,1,0,4,2,1,1
+HLT003-ONC-TTE-001-00044,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,59,Male,22.0,33.7,Low,1,0,1,1,0,,,,,29.71,1,0,15,7,2,1
+HLT003-ONC-TTE-001-00045,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,58,Male,30.9,56.6,Moderate,1,0,1,0,0,,,,,35.15,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00046,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,31.9,60.9,Moderate,0,0,1,1,0,,,,,29.84,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00047,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Female,29.0,40.7,Low,0,1,1,1,0,,,,,3.59,0,1,20,8,6,1
+HLT003-ONC-TTE-001-00048,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Female,29.8,55.5,Moderate,0,0,1,1,0,,,,,8.82,1,0,3,2,1,1
+HLT003-ONC-TTE-001-00049,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,65,Female,27.0,65.3,High,0,1,1,1,0,,,,,52.0,0,1,5,3,2,1
+HLT003-ONC-TTE-001-00050,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,57,Female,37.1,66.1,High,1,0,1,1,0,,,,,2.26,1,0,15,9,4,1
+HLT003-ONC-TTE-001-00051,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Male,23.3,82.9,High,0,0,1,1,0,,,,,38.27,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00052,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Female,25.1,78.0,High,0,0,1,1,0,,,,,10.18,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00053,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,39,Male,28.6,37.0,Low,0,0,1,1,0,,,,,17.45,1,0,8,3,1,1
+HLT003-ONC-TTE-001-00054,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,33.6,85.3,High,1,0,1,1,0,,,,,15.45,0,1,10,3,0,1
+HLT003-ONC-TTE-001-00055,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,51,Male,19.8,45.4,Low,0,0,1,1,0,,,,,52.0,0,1,20,9,4,1
+HLT003-ONC-TTE-001-00056,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,49,Male,20.9,73.8,High,0,0,1,1,0,,,,,11.92,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00057,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,16.7,56.2,Moderate,0,0,1,1,0,,,,,52.0,0,1,20,8,5,1
+HLT003-ONC-TTE-001-00058,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,74,Male,28.7,47.6,Moderate,0,1,1,1,0,,,,,1.93,0,1,8,3,2,1
+HLT003-ONC-TTE-001-00059,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,22.0,22.5,Low,1,0,1,1,0,,,,,14.36,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00060,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,68,Female,26.3,51.9,Moderate,0,1,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00061,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,36,Male,32.3,26.9,Low,0,0,1,1,0,,,,,20.41,1,0,3,2,1,1
+HLT003-ONC-TTE-001-00062,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,52,Male,24.8,72.4,High,1,0,1,1,0,,,,,19.86,0,1,7,4,2,1
+HLT003-ONC-TTE-001-00063,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,58,Female,29.8,82.3,High,0,0,1,1,0,,,,,35.24,0,1,12,3,2,1
+HLT003-ONC-TTE-001-00064,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Female,26.8,40.7,Low,0,0,1,1,0,,,,,2.43,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00065,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,65,Female,32.4,60.4,Moderate,0,1,1,1,0,,,,,0.53,1,0,20,11,5,1
+HLT003-ONC-TTE-001-00066,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Male,31.3,41.9,Low,1,1,1,1,0,,,,,38.74,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00067,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,52,Female,24.5,43.7,Low,1,0,1,0,1,,,,,48.71,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00068,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,51,Male,27.5,68.9,High,0,0,1,1,0,,,,,13.44,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00069,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Male,34.6,54.3,Moderate,0,1,1,0,0,,,,,10.95,0,1,20,12,10,1
+HLT003-ONC-TTE-001-00070,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Female,30.8,86.3,High,0,0,1,1,0,,,,,36.64,0,1,6,3,2,1
+HLT003-ONC-TTE-001-00071,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,41,Female,20.4,46.3,Moderate,0,0,1,1,0,,,,,0.21,0,1,11,5,3,1
+HLT003-ONC-TTE-001-00072,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,43,Female,32.3,73.0,High,0,0,1,1,0,,,,,14.33,1,0,4,1,0,1
+HLT003-ONC-TTE-001-00073,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,45,Female,22.2,56.8,Moderate,0,0,1,1,0,,,,,14.31,1,0,20,9,4,1
+HLT003-ONC-TTE-001-00074,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,62,Female,36.7,69.3,High,1,0,1,1,0,,,,,9.24,1,0,15,9,6,1
+HLT003-ONC-TTE-001-00075,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Male,34.4,47.0,Moderate,1,0,1,1,0,,,,,13.89,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00076,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,65,Male,30.2,54.1,Moderate,1,1,1,1,0,,,,,16.19,0,1,6,4,3,1
+HLT003-ONC-TTE-001-00077,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Male,29.4,52.9,Moderate,0,0,1,1,0,,,,,8.01,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00078,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,58,Male,27.3,40.0,Low,1,0,1,1,0,,,,,52.0,0,1,8,5,2,1
+HLT003-ONC-TTE-001-00079,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Female,32.4,66.9,High,1,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00080,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,26.3,66.7,High,0,0,1,1,0,,,,,0.97,0,1,2,2,2,1
+HLT003-ONC-TTE-001-00081,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,62,Female,29.9,65.7,High,1,0,1,1,0,,,,,1.22,0,1,17,11,5,1
+HLT003-ONC-TTE-001-00082,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,49,Female,33.6,82.7,High,1,0,1,1,0,,,,,26.63,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00083,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Female,25.2,81.1,High,0,0,1,1,0,,,,,24.62,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00084,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Male,24.9,48.3,Moderate,0,0,1,1,0,,,,,26.57,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00085,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Male,21.6,61.7,Moderate,0,0,1,1,0,,,,,8.04,0,1,2,1,0,1
+HLT003-ONC-TTE-001-00086,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,22.3,43.8,Low,0,0,1,0,1,,,,,13.12,1,0,7,3,1,1
+HLT003-ONC-TTE-001-00087,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Female,17.9,55.4,Moderate,1,0,1,1,0,,,,,12.66,0,1,12,5,1,1
+HLT003-ONC-TTE-001-00088,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,57,Female,32.7,44.2,Low,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00089,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Female,39.0,84.2,High,0,0,1,1,0,,,,,16.22,1,0,11,6,5,1
+HLT003-ONC-TTE-001-00090,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Female,36.8,61.5,Moderate,0,0,1,1,0,,,,,52.0,0,1,8,6,2,1
+HLT003-ONC-TTE-001-00091,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Male,19.1,51.1,Moderate,0,0,1,1,0,,,,,9.97,1,0,6,2,1,1
+HLT003-ONC-TTE-001-00092,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,32.7,76.5,High,0,0,1,1,0,,,,,34.06,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00093,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Male,36.7,15.9,Low,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00094,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,25.9,18.7,Low,0,0,1,1,0,,,,,21.4,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00095,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,36,Female,29.1,69.3,High,1,0,1,1,0,,,,,52.0,0,1,5,1,1,1
+HLT003-ONC-TTE-001-00096,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,39,Male,16.9,56.1,Moderate,0,0,1,1,0,,,,,32.98,0,1,7,4,1,1
+HLT003-ONC-TTE-001-00097,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,41,Male,30.0,59.5,Moderate,0,0,1,1,0,,,,,21.76,1,0,4,1,0,1
+HLT003-ONC-TTE-001-00098,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,45,Male,22.3,31.1,Low,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00099,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Female,29.7,54.6,Moderate,0,0,1,1,0,,,,,12.23,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00100,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,46,Male,19.4,91.1,High,1,0,1,1,0,,,,,10.75,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00101,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Male,31.6,69.8,High,0,0,1,1,0,,,,,2.11,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00102,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,72,Male,34.4,58.1,Moderate,0,1,1,0,1,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00103,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Male,24.0,47.1,Moderate,0,0,1,1,0,,,,,5.49,1,0,4,2,1,1
+HLT003-ONC-TTE-001-00104,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,65,Male,21.9,47.9,Moderate,1,1,1,1,0,,,,,4.14,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00105,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,45,Male,16.0,16.7,Low,1,0,1,1,0,,,,,9.12,1,0,9,4,3,1
+HLT003-ONC-TTE-001-00106,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Male,27.0,59.6,Moderate,0,0,1,1,0,,,,,22.53,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00107,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,45,Male,25.1,70.2,High,0,0,1,1,0,,,,,23.48,1,0,5,3,2,1
+HLT003-ONC-TTE-001-00108,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Male,19.5,26.6,Low,0,0,1,1,0,,,,,2.89,1,0,16,8,6,1
+HLT003-ONC-TTE-001-00109,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,67,Male,31.1,43.1,Low,1,1,1,0,1,,,,,11.98,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00110,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,36,Male,25.9,34.2,Low,1,0,1,1,0,,,,,7.7,1,0,20,9,8,1
+HLT003-ONC-TTE-001-00111,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,22.3,37.6,Low,1,0,1,1,0,,,,,4.01,0,1,6,2,1,1
+HLT003-ONC-TTE-001-00112,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Male,25.3,56.0,Moderate,0,0,1,1,0,,,,,31.91,1,0,8,2,1,1
+HLT003-ONC-TTE-001-00113,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,49,Male,34.7,17.5,Low,0,0,1,1,0,,,,,52.0,0,1,5,3,1,1
+HLT003-ONC-TTE-001-00114,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,39,Male,32.0,66.1,High,0,0,1,1,0,,,,,14.58,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00115,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,57,Male,27.7,68.6,High,0,0,1,1,0,,,,,17.32,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00116,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,50,Male,32.1,50.5,Moderate,1,0,1,1,0,,,,,3.69,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00117,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Male,21.8,10.3,Low,0,0,1,1,0,,,,,22.08,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00118,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,57,Female,28.7,37.1,Low,1,0,1,1,0,,,,,36.68,1,0,14,9,5,1
+HLT003-ONC-TTE-001-00119,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,76,Male,29.4,77.2,High,1,1,1,1,0,,,,,52.0,0,1,14,6,3,1
+HLT003-ONC-TTE-001-00120,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Male,25.8,10.0,Low,0,0,1,1,0,,,,,24.31,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00121,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,31.0,48.7,Moderate,1,0,1,0,1,,,,,18.48,0,1,15,8,5,1
+HLT003-ONC-TTE-001-00122,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,24.0,33.8,Low,0,0,1,1,0,,,,,7.68,0,1,11,4,1,1
+HLT003-ONC-TTE-001-00123,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,31.5,69.5,High,0,0,1,1,0,,,,,52.0,0,1,15,6,4,1
+HLT003-ONC-TTE-001-00124,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,73,Female,31.7,42.8,Low,0,1,1,1,0,,,,,31.87,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00125,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Female,16.0,62.3,High,0,1,1,1,0,,,,,5.26,0,1,20,10,6,1
+HLT003-ONC-TTE-001-00126,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Male,35.4,65.2,High,0,0,1,1,0,,,,,17.69,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00127,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,74,Male,16.0,88.1,High,0,1,1,1,0,,,,,24.54,1,0,20,10,7,1
+HLT003-ONC-TTE-001-00128,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,42,Male,24.9,51.3,Moderate,1,0,1,1,0,,,,,31.59,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00129,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,49,Male,34.4,61.8,High,1,0,1,1,0,,,,,52.0,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00130,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,45,Female,26.7,28.3,Low,0,0,1,1,0,,,,,52.0,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00131,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Male,20.0,76.4,High,0,0,1,1,0,,,,,1.12,1,0,7,2,2,1
+HLT003-ONC-TTE-001-00132,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,40,Male,22.2,41.3,Low,1,0,1,1,0,,,,,52.0,0,1,2,2,1,1
+HLT003-ONC-TTE-001-00133,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Female,34.5,44.9,Low,0,0,1,1,0,,,,,25.87,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00134,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Male,17.4,54.6,Moderate,0,0,1,0,0,,,,,27.93,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00135,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,39,Male,35.0,26.9,Low,0,0,1,1,0,,,,,52.0,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00136,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Female,28.2,59.1,Moderate,0,0,1,1,0,,,,,1.98,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00137,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Male,21.6,72.4,High,0,0,1,1,0,,,,,38.82,1,0,10,8,6,1
+HLT003-ONC-TTE-001-00138,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Male,25.1,60.3,Moderate,0,1,1,0,1,,,,,23.05,0,1,20,15,10,1
+HLT003-ONC-TTE-001-00139,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,80,Male,22.6,26.4,Low,0,1,1,0,1,,,,,50.47,1,0,10,4,1,1
+HLT003-ONC-TTE-001-00140,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,85,Female,33.5,52.8,Moderate,1,1,1,1,0,,,,,22.94,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00141,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Male,32.7,68.4,High,0,0,1,1,0,,,,,10.08,1,0,5,1,1,1
+HLT003-ONC-TTE-001-00142,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,45,Male,18.5,21.2,Low,1,0,1,1,0,,,,,52.0,0,1,10,4,4,1
+HLT003-ONC-TTE-001-00143,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,31,Male,26.2,35.7,Low,0,0,1,1,0,,,,,44.97,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00144,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,60,Male,23.5,70.8,High,1,0,1,1,0,,,,,35.97,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00145,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,47,Female,36.0,59.9,Moderate,1,0,1,1,0,,,,,52.0,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00146,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,52,Male,20.7,62.4,High,1,0,1,1,0,,,,,17.19,1,0,6,3,3,1
+HLT003-ONC-TTE-001-00147,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,49,Female,37.8,88.5,High,0,0,1,1,0,,,,,7.77,1,0,3,0,0,1
+HLT003-ONC-TTE-001-00148,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,28.3,63.4,High,1,0,1,1,0,,,,,28.95,0,1,3,2,1,1
+HLT003-ONC-TTE-001-00149,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,69,Female,21.8,66.8,High,1,1,1,1,0,,,,,21.55,1,0,11,8,4,1
+HLT003-ONC-TTE-001-00150,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Male,24.6,100.0,High,0,0,1,1,0,,,,,0.08,1,0,6,3,2,1
+HLT003-ONC-TTE-001-00151,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,23.9,51.2,Moderate,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00152,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,44,Female,21.1,40.6,Low,0,0,1,1,0,,,,,36.21,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00153,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,36,Male,29.0,62.7,High,0,0,1,1,0,,,,,43.25,1,0,19,5,3,1
+HLT003-ONC-TTE-001-00154,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Female,21.4,62.9,High,0,0,1,1,0,,,,,17.86,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00155,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,16.0,45.5,Moderate,1,0,1,1,0,,,,,23.13,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00156,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,78,Male,26.3,36.4,Low,1,1,1,1,0,,,,,13.44,1,0,11,5,4,1
+HLT003-ONC-TTE-001-00157,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Female,18.0,96.6,High,0,0,1,0,1,,,,,17.6,1,0,20,11,7,1
+HLT003-ONC-TTE-001-00158,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,68,Male,24.1,60.9,Moderate,1,1,1,1,0,,,,,45.07,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00159,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,51,Female,23.2,41.8,Low,0,0,1,0,1,,,,,32.02,1,0,4,3,1,1
+HLT003-ONC-TTE-001-00160,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,42,Female,23.4,71.5,High,0,0,1,1,0,,,,,52.0,0,1,5,2,1,1
+HLT003-ONC-TTE-001-00161,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,45,Male,40.1,53.0,Moderate,0,0,1,0,1,,,,,38.24,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00162,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,48,Female,28.8,50.4,Moderate,0,0,1,1,0,,,,,52.0,0,1,8,2,0,1
+HLT003-ONC-TTE-001-00163,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,82,Male,29.9,65.1,High,0,1,1,1,0,,,,,6.31,1,0,20,7,4,1
+HLT003-ONC-TTE-001-00164,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,47,Female,18.2,31.7,Low,0,0,1,1,0,,,,,2.12,1,0,4,0,0,1
+HLT003-ONC-TTE-001-00165,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Female,24.7,61.3,Moderate,0,1,1,1,0,,,,,1.93,1,0,5,4,3,1
+HLT003-ONC-TTE-001-00166,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,29.7,89.4,High,1,0,1,0,1,,,,,3.32,1,0,6,3,1,1
+HLT003-ONC-TTE-001-00167,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,68,Male,22.6,63.4,High,1,1,1,1,0,,,,,10.77,0,1,3,1,0,1
+HLT003-ONC-TTE-001-00168,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Male,33.8,48.2,Moderate,0,0,1,0,1,,,,,17.12,1,0,6,1,1,1
+HLT003-ONC-TTE-001-00169,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,55,Male,21.5,45.9,Moderate,1,0,1,1,0,,,,,3.81,0,1,4,0,0,1
+HLT003-ONC-TTE-001-00170,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Male,26.8,47.6,Moderate,0,0,1,0,1,,,,,14.92,0,1,20,3,3,1
+HLT003-ONC-TTE-001-00171,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,49,Male,25.1,50.4,Moderate,0,0,1,1,0,,,,,13.85,1,0,5,2,1,1
+HLT003-ONC-TTE-001-00172,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Male,29.5,48.2,Moderate,0,0,1,1,0,,,,,8.92,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00173,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Male,24.8,71.5,High,0,0,1,1,0,,,,,5.45,0,1,5,3,2,1
+HLT003-ONC-TTE-001-00174,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,42,Female,26.9,23.8,Low,0,0,1,1,0,,,,,52.0,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00175,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,41,Female,27.1,70.5,High,0,0,1,1,0,,,,,51.81,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00176,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,24.2,48.2,Moderate,1,0,1,1,0,,,,,5.76,1,0,3,2,1,1
+HLT003-ONC-TTE-001-00177,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,75,Male,31.3,61.8,High,0,1,1,1,0,,,,,15.52,1,0,20,8,5,1
+HLT003-ONC-TTE-001-00178,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Female,29.9,34.7,Low,1,0,1,1,0,,,,,7.05,1,0,10,4,2,1
+HLT003-ONC-TTE-001-00179,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,55,Female,28.0,78.9,High,0,0,1,1,0,,,,,32.6,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00180,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Male,26.0,77.4,High,0,0,1,1,0,,,,,10.92,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00181,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,72,Male,33.1,72.3,High,0,1,1,1,0,,,,,5.74,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00182,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,27.1,27.7,Low,0,0,1,1,0,,,,,7.38,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00183,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Male,26.7,69.9,High,0,0,1,1,0,,,,,52.0,0,1,5,2,1,1
+HLT003-ONC-TTE-001-00184,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,70,Male,29.1,62.3,High,1,1,1,1,0,,,,,45.65,1,0,20,7,6,1
+HLT003-ONC-TTE-001-00185,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Female,38.3,26.1,Low,0,0,1,1,0,,,,,48.24,0,1,16,7,4,1
+HLT003-ONC-TTE-001-00186,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,75,Male,20.7,54.6,Moderate,0,1,1,1,0,,,,,20.78,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00187,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Male,33.0,61.6,Moderate,0,0,1,1,0,,,,,6.16,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00188,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Female,17.5,65.0,High,0,0,1,1,0,,,,,3.95,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00189,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,40,Female,29.8,58.2,Moderate,1,0,1,0,1,,,,,2.92,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00190,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,76,Male,37.6,60.2,Moderate,1,1,1,0,1,,,,,10.13,1,0,2,2,1,1
+HLT003-ONC-TTE-001-00191,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,77,Female,31.3,81.5,High,1,1,1,1,0,,,,,39.59,1,0,2,2,1,1
+HLT003-ONC-TTE-001-00192,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,54,Female,29.5,77.1,High,1,0,1,0,1,,,,,52.0,0,1,6,4,1,1
+HLT003-ONC-TTE-001-00193,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Female,25.2,10.0,Low,0,0,1,1,0,,,,,44.15,0,1,5,1,1,1
+HLT003-ONC-TTE-001-00194,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,74,Female,28.7,49.3,Moderate,0,1,1,1,0,,,,,21.44,1,0,2,2,0,1
+HLT003-ONC-TTE-001-00195,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,43,Male,27.0,52.0,Moderate,0,0,1,1,0,,,,,52.0,0,1,4,3,3,1
+HLT003-ONC-TTE-001-00196,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,23.9,23.5,Low,0,0,1,1,0,,,,,22.12,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00197,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Female,26.8,56.7,Moderate,0,0,1,1,0,,,,,2.43,1,0,17,4,1,1
+HLT003-ONC-TTE-001-00198,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Male,29.7,77.5,High,0,0,1,1,0,,,,,9.93,0,1,4,2,0,1
+HLT003-ONC-TTE-001-00199,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,24.1,35.4,Low,1,0,1,1,0,,,,,5.0,0,1,4,2,1,1
+HLT003-ONC-TTE-001-00200,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,55,Female,23.8,61.1,Moderate,0,0,1,1,0,,,,,48.09,0,1,4,1,1,1
+HLT003-ONC-TTE-001-00201,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Male,20.6,38.5,Low,1,0,1,0,1,,,,,4.33,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00202,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,73,Female,30.8,42.9,Low,0,1,1,1,0,,,,,22.75,1,0,11,4,1,1
+HLT003-ONC-TTE-001-00203,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,58,Male,31.7,81.6,High,0,0,1,1,0,,,,,30.76,1,0,7,4,1,1
+HLT003-ONC-TTE-001-00204,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,64,Female,29.8,45.2,Low,0,0,1,1,0,,,,,29.46,0,1,13,6,4,1
+HLT003-ONC-TTE-001-00205,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,32,Male,34.1,63.3,High,0,0,1,1,0,,,,,18.35,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00206,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,29.0,21.3,Low,1,0,1,1,0,,,,,44.57,0,1,2,1,0,1
+HLT003-ONC-TTE-001-00207,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Female,30.8,88.5,High,0,0,1,1,0,,,,,2.53,0,1,8,2,2,1
+HLT003-ONC-TTE-001-00208,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,42,Male,30.3,65.8,High,0,0,1,1,0,,,,,30.01,0,1,12,5,4,1
+HLT003-ONC-TTE-001-00209,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,46,Female,28.0,51.7,Moderate,0,0,1,1,0,,,,,41.51,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00210,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Female,25.4,65.4,High,0,0,1,1,0,,,,,16.54,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00211,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Female,41.3,29.6,Low,0,1,1,0,1,,,,,39.83,1,0,12,5,2,1
+HLT003-ONC-TTE-001-00212,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,41,Female,25.9,76.3,High,0,0,1,1,0,,,,,22.13,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00213,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,57,Female,24.6,49.2,Moderate,0,0,1,1,0,,,,,11.14,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00214,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,51,Male,31.0,51.3,Moderate,0,0,1,1,0,,,,,3.98,0,1,10,7,4,1
+HLT003-ONC-TTE-001-00215,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,30.0,46.2,Moderate,0,0,1,1,0,,,,,16.75,1,0,19,8,3,1
+HLT003-ONC-TTE-001-00216,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,69,Male,20.4,44.5,Low,0,1,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00217,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,63,Female,35.0,67.5,High,0,0,1,1,0,,,,,44.46,1,0,9,4,3,1
+HLT003-ONC-TTE-001-00218,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,73,Female,28.0,59.6,Moderate,0,1,1,1,0,,,,,32.04,0,1,8,3,3,1
+HLT003-ONC-TTE-001-00219,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,55,Male,22.1,66.7,High,0,0,1,1,0,,,,,4.25,1,0,20,6,1,1
+HLT003-ONC-TTE-001-00220,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Male,35.4,54.8,Moderate,1,0,1,1,0,,,,,46.27,1,0,9,4,3,1
+HLT003-ONC-TTE-001-00221,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,54,Female,32.1,64.2,High,1,0,1,1,0,,,,,44.07,0,1,3,1,0,1
+HLT003-ONC-TTE-001-00222,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Male,21.2,47.5,Moderate,0,0,1,1,0,,,,,52.0,0,1,4,2,1,1
+HLT003-ONC-TTE-001-00223,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,38.8,95.1,High,0,0,1,1,0,,,,,32.61,1,0,14,5,2,1
+HLT003-ONC-TTE-001-00224,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,43,Male,32.3,26.8,Low,0,0,1,1,0,,,,,21.64,0,1,15,7,4,1
+HLT003-ONC-TTE-001-00225,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,58,Female,28.4,77.7,High,1,0,1,1,0,,,,,48.68,0,1,5,2,1,1
+HLT003-ONC-TTE-001-00226,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,37.7,79.6,High,0,0,1,1,0,,,,,3.31,1,0,5,3,1,1
+HLT003-ONC-TTE-001-00227,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,85,Male,29.4,39.7,Low,0,1,1,1,0,,,,,17.41,1,0,18,6,3,1
+HLT003-ONC-TTE-001-00228,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,79,Female,28.3,95.1,High,0,1,1,1,0,,,,,14.96,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00229,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,46,Female,24.7,72.9,High,1,0,1,1,0,,,,,19.65,0,1,3,0,0,1
+HLT003-ONC-TTE-001-00230,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,53,Male,31.9,72.5,High,0,0,1,1,0,,,,,18.32,0,1,6,3,2,1
+HLT003-ONC-TTE-001-00231,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,39,Male,31.3,55.5,Moderate,0,0,1,1,0,,,,,2.08,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00232,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,49,Female,28.6,51.1,Moderate,0,0,1,1,0,,,,,15.86,1,0,6,5,4,1
+HLT003-ONC-TTE-001-00233,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Female,23.9,51.2,Moderate,0,0,1,1,0,,,,,52.0,0,1,3,1,1,1
+HLT003-ONC-TTE-001-00234,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,71,Male,29.3,62.0,High,0,1,1,1,0,,,,,3.99,1,0,16,5,2,1
+HLT003-ONC-TTE-001-00235,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,48,Male,28.1,80.2,High,0,0,1,0,1,,,,,52.0,0,1,14,3,2,1
+HLT003-ONC-TTE-001-00236,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,49,Female,20.8,58.3,Moderate,0,0,1,0,0,,,,,7.06,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00237,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,31,Female,20.0,38.6,Low,0,0,1,1,0,,,,,25.38,0,1,4,2,0,1
+HLT003-ONC-TTE-001-00238,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,31.8,69.8,High,0,0,1,0,0,,,,,34.39,1,0,3,3,1,1
+HLT003-ONC-TTE-001-00239,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,44,Female,16.0,71.6,High,0,0,1,1,0,,,,,24.67,1,0,3,2,1,1
+HLT003-ONC-TTE-001-00240,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Male,29.7,66.8,High,0,0,1,1,0,,,,,0.38,1,0,4,1,0,1
+HLT003-ONC-TTE-001-00241,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,46,Female,25.7,68.4,High,1,0,1,1,0,,,,,52.0,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00242,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,36.1,50.1,Moderate,0,0,1,1,0,,,,,6.73,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00243,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,35,Female,25.6,38.3,Low,0,0,1,1,0,,,,,2.34,1,0,5,3,0,1
+HLT003-ONC-TTE-001-00244,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,39,Male,32.3,39.4,Low,1,0,1,1,0,,,,,8.04,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00245,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,82,Male,26.2,25.6,Low,0,1,1,0,0,,,,,15.35,0,1,7,3,2,1
+HLT003-ONC-TTE-001-00246,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,41,Female,29.2,59.3,Moderate,1,0,1,1,0,,,,,5.77,0,1,3,3,0,1
+HLT003-ONC-TTE-001-00247,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,43,Male,32.8,53.5,Moderate,0,0,1,1,0,,,,,51.17,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00248,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,79,Female,25.8,47.1,Moderate,1,1,1,1,0,,,,,4.17,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00249,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,85,Male,34.3,10.0,Low,0,1,1,0,1,,,,,10.48,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00250,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Female,22.7,32.5,Low,1,0,1,1,0,,,,,37.49,1,0,12,4,4,1
+HLT003-ONC-TTE-001-00251,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Female,30.2,75.2,High,0,0,1,1,0,,,,,26.82,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00252,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Male,33.9,43.0,Low,0,0,1,1,0,,,,,3.76,0,1,4,2,1,1
+HLT003-ONC-TTE-001-00253,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,77,Male,32.3,61.5,Moderate,0,1,1,1,0,,,,,38.93,1,0,8,2,1,1
+HLT003-ONC-TTE-001-00254,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,45,Female,39.6,30.0,Low,0,0,1,1,0,,,,,12.72,1,0,3,1,0,1
+HLT003-ONC-TTE-001-00255,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,54,Female,24.1,80.9,High,0,0,1,1,0,,,,,28.83,0,1,2,2,1,1
+HLT003-ONC-TTE-001-00256,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Male,20.5,52.4,Moderate,0,1,1,1,0,,,,,5.81,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00257,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,22.7,60.2,Moderate,1,0,1,1,0,,,,,13.58,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00258,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Female,32.3,96.9,High,0,0,1,1,0,,,,,9.87,1,0,6,2,1,1
+HLT003-ONC-TTE-001-00259,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,55,Male,31.4,82.3,High,1,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00260,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,40,Male,29.1,49.5,Moderate,0,0,1,1,0,,,,,46.36,1,0,13,6,4,1
+HLT003-ONC-TTE-001-00261,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Male,22.0,44.3,Low,0,0,1,1,0,,,,,19.76,1,0,13,2,2,1
+HLT003-ONC-TTE-001-00262,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,32.9,49.1,Moderate,0,0,1,1,0,,,,,6.96,1,0,5,4,1,1
+HLT003-ONC-TTE-001-00263,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,21.4,64.2,High,0,0,1,1,0,,,,,6.05,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00264,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Male,35.2,53.1,Moderate,0,0,1,1,0,,,,,45.08,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00265,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Female,45.1,47.9,Moderate,0,0,1,1,0,,,,,52.0,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00266,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,69,Male,30.6,81.4,High,0,1,1,1,0,,,,,27.17,1,0,4,3,1,1
+HLT003-ONC-TTE-001-00267,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Female,31.9,52.9,Moderate,0,0,1,1,0,,,,,11.95,1,0,4,2,0,1
+HLT003-ONC-TTE-001-00268,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Male,25.6,96.4,High,0,0,1,1,0,,,,,20.08,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00269,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,57,Male,18.0,56.6,Moderate,1,0,1,0,0,,,,,20.66,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00270,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,57,Female,25.0,87.1,High,1,0,1,1,0,,,,,14.38,0,1,5,3,0,1
+HLT003-ONC-TTE-001-00271,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Female,22.2,61.4,Moderate,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00272,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Male,20.1,72.3,High,0,0,1,1,0,,,,,10.82,1,0,2,2,1,1
+HLT003-ONC-TTE-001-00273,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,55,Male,38.5,42.0,Low,1,0,1,1,0,,,,,5.96,0,1,2,1,0,1
+HLT003-ONC-TTE-001-00274,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,82,Male,30.1,39.6,Low,1,1,1,1,0,,,,,18.58,1,0,12,3,3,1
+HLT003-ONC-TTE-001-00275,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,75,Female,30.7,63.3,High,1,1,1,1,0,,,,,45.5,0,1,5,3,2,1
+HLT003-ONC-TTE-001-00276,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Male,26.7,72.8,High,0,0,1,1,0,,,,,10.29,0,1,5,2,1,1
+HLT003-ONC-TTE-001-00277,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,47,Male,27.5,55.7,Moderate,1,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00278,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,43,Male,34.1,31.8,Low,0,0,1,0,0,,,,,8.67,0,1,3,1,1,1
+HLT003-ONC-TTE-001-00279,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,71,Male,28.3,30.5,Low,0,1,1,1,0,,,,,26.45,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00280,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Female,31.6,29.3,Low,1,0,1,1,0,,,,,26.31,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00281,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Female,27.4,23.2,Low,0,0,1,1,0,,,,,29.92,0,1,17,4,3,1
+HLT003-ONC-TTE-001-00282,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,36,Male,26.5,57.0,Moderate,0,0,1,1,0,,,,,4.77,1,0,6,2,2,1
+HLT003-ONC-TTE-001-00283,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,68,Male,20.3,75.3,High,0,1,1,0,1,,,,,6.45,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00284,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Male,17.0,54.8,Moderate,0,0,1,1,0,,,,,10.54,0,1,5,1,1,1
+HLT003-ONC-TTE-001-00285,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,43,Male,27.0,14.3,Low,0,0,1,0,0,,,,,3.4,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00286,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,51,Female,28.8,51.6,Moderate,1,0,1,1,0,,,,,23.27,1,0,18,9,7,1
+HLT003-ONC-TTE-001-00287,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Female,21.0,52.1,Moderate,0,0,1,1,0,,,,,43.4,1,0,7,1,0,1
+HLT003-ONC-TTE-001-00288,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,57,Female,28.3,92.7,High,0,0,1,0,1,,,,,27.27,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00289,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,53,Female,28.8,28.8,Low,1,0,1,1,0,,,,,24.79,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00290,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,16.0,48.0,Moderate,0,0,1,1,0,,,,,52.0,0,1,20,6,2,1
+HLT003-ONC-TTE-001-00291,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Female,23.2,85.7,High,0,0,1,1,0,,,,,35.03,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00292,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,58,Male,30.9,63.1,High,1,0,1,1,0,,,,,4.67,1,0,6,3,1,1
+HLT003-ONC-TTE-001-00293,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,74,Male,30.7,65.1,High,1,1,1,1,0,,,,,52.0,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00294,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,26,Male,21.8,57.1,Moderate,0,0,1,1,0,,,,,12.86,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00295,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,54,Female,29.4,60.9,Moderate,1,0,1,1,0,,,,,10.2,1,0,6,3,3,1
+HLT003-ONC-TTE-001-00296,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,34.4,69.0,High,1,0,1,1,0,,,,,30.37,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00297,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Female,33.0,40.4,Low,0,0,1,1,0,,,,,2.29,0,1,2,1,0,1
+HLT003-ONC-TTE-001-00298,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Female,27.9,70.8,High,1,0,1,1,0,,,,,10.18,0,1,17,6,2,1
+HLT003-ONC-TTE-001-00299,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,35,Female,25.8,30.3,Low,0,0,1,1,0,,,,,6.51,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00300,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Male,24.8,60.9,Moderate,0,0,1,0,1,,,,,6.69,1,0,3,0,0,1
+HLT003-ONC-TTE-001-00301,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,77,Male,31.2,58.2,Moderate,0,1,1,1,0,,,,,13.61,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00302,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,38,Male,29.6,43.9,Low,1,0,1,1,0,,,,,52.0,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00303,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,67,Female,32.2,54.6,Moderate,0,1,1,1,0,,,,,7.34,0,1,6,3,2,1
+HLT003-ONC-TTE-001-00304,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,53,Female,29.3,43.8,Low,1,0,1,1,0,,,,,4.86,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00305,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,33.2,35.7,Low,0,0,1,0,0,,,,,1.6,0,1,2,2,1,1
+HLT003-ONC-TTE-001-00306,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,29.0,48.6,Moderate,0,0,1,1,0,,,,,10.06,1,0,5,2,2,1
+HLT003-ONC-TTE-001-00307,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Male,33.1,35.1,Low,0,0,1,0,1,,,,,22.88,1,0,17,9,3,1
+HLT003-ONC-TTE-001-00308,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,72,Male,33.6,60.8,Moderate,1,1,1,1,0,,,,,14.69,1,0,5,3,3,1
+HLT003-ONC-TTE-001-00309,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,63,Female,23.8,34.3,Low,1,0,1,1,0,,,,,17.94,1,0,6,3,2,1
+HLT003-ONC-TTE-001-00310,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,77,Female,18.0,67.8,High,0,1,1,1,0,,,,,18.03,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00311,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,71,Male,37.5,33.7,Low,1,1,1,1,0,,,,,9.78,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00312,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,30.0,44.8,Low,1,0,1,1,0,,,,,15.08,1,0,12,4,2,1
+HLT003-ONC-TTE-001-00313,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,77,Male,18.6,43.8,Low,0,1,1,0,0,,,,,52.0,0,1,3,0,0,1
+HLT003-ONC-TTE-001-00314,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,24.4,78.9,High,0,0,1,1,0,,,,,16.29,1,0,3,0,0,1
+HLT003-ONC-TTE-001-00315,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,66,Male,33.0,60.9,Moderate,1,1,1,1,0,,,,,0.89,1,0,20,10,4,1
+HLT003-ONC-TTE-001-00316,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,26.9,51.2,Moderate,0,0,1,1,0,,,,,27.17,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00317,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,57,Female,25.5,64.0,High,0,0,1,1,0,,,,,28.98,1,0,4,3,2,1
+HLT003-ONC-TTE-001-00318,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Male,36.6,17.1,Low,0,0,1,1,0,,,,,30.65,1,0,9,5,4,1
+HLT003-ONC-TTE-001-00319,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,68,Male,22.4,54.2,Moderate,0,1,1,1,0,,,,,11.94,1,0,10,6,4,1
+HLT003-ONC-TTE-001-00320,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Male,23.9,91.0,High,0,0,1,1,0,,,,,15.16,0,1,12,4,3,1
+HLT003-ONC-TTE-001-00321,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Male,29.7,57.4,Moderate,0,1,1,1,0,,,,,12.81,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00322,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Female,30.8,56.2,Moderate,0,0,1,1,0,,,,,0.52,1,0,16,11,5,1
+HLT003-ONC-TTE-001-00323,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,71,Female,31.4,64.9,High,0,1,1,1,0,,,,,20.41,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00324,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Female,33.8,71.1,High,1,1,1,1,0,,,,,31.08,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00325,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,78,Male,29.7,19.0,Low,1,1,1,0,1,,,,,34.19,1,0,13,5,3,1
+HLT003-ONC-TTE-001-00326,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,65,Female,31.3,24.7,Low,1,1,1,1,0,,,,,28.37,1,0,16,7,3,1
+HLT003-ONC-TTE-001-00327,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,38,Male,27.0,58.8,Moderate,0,0,1,1,0,,,,,39.96,0,1,5,1,0,1
+HLT003-ONC-TTE-001-00328,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Male,28.9,42.1,Low,0,0,1,0,0,,,,,13.8,1,0,7,4,3,1
+HLT003-ONC-TTE-001-00329,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,42,Male,29.1,78.6,High,0,0,1,0,1,,,,,27.78,1,0,19,11,10,1
+HLT003-ONC-TTE-001-00330,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,50,Female,29.7,49.3,Moderate,0,0,1,1,0,,,,,17.2,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00331,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,75,Female,33.0,20.2,Low,0,1,1,1,0,,,,,21.62,1,0,5,1,1,1
+HLT003-ONC-TTE-001-00332,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Female,31.7,32.2,Low,1,0,1,1,0,,,,,4.04,1,0,2,2,0,1
+HLT003-ONC-TTE-001-00333,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,48,Male,28.8,10.0,Low,0,0,1,1,0,,,,,10.12,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00334,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,23.8,50.8,Moderate,0,0,1,1,0,,,,,0.67,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00335,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,57,Female,28.9,51.6,Moderate,1,0,1,1,0,,,,,4.12,1,0,5,2,0,1
+HLT003-ONC-TTE-001-00336,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Female,28.3,47.4,Moderate,0,0,1,1,0,,,,,15.44,1,0,3,1,1,1
+HLT003-ONC-TTE-001-00337,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,48,Male,29.6,74.4,High,0,0,1,0,0,,,,,6.06,1,0,7,3,1,1
+HLT003-ONC-TTE-001-00338,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Male,41.3,76.6,High,0,0,1,1,0,,,,,9.06,1,0,4,3,0,1
+HLT003-ONC-TTE-001-00339,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Male,25.5,51.9,Moderate,0,1,1,1,0,,,,,3.15,0,1,2,2,2,1
+HLT003-ONC-TTE-001-00340,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,64,Female,30.9,16.6,Low,1,0,1,1,0,,,,,1.9,1,0,2,2,1,1
+HLT003-ONC-TTE-001-00341,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,29,Male,34.7,66.1,High,1,0,1,1,0,,,,,19.23,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00342,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Female,29.1,65.0,High,1,0,1,1,0,,,,,40.06,0,1,8,1,1,1
+HLT003-ONC-TTE-001-00343,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,57,Male,42.1,60.6,Moderate,1,0,1,1,0,,,,,20.16,1,0,6,3,2,1
+HLT003-ONC-TTE-001-00344,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Female,26.3,72.7,High,0,0,1,0,0,,,,,21.53,1,0,15,8,4,1
+HLT003-ONC-TTE-001-00345,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,76,Male,30.4,34.0,Low,0,1,1,0,1,,,,,52.0,0,1,7,4,3,1
+HLT003-ONC-TTE-001-00346,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,32,Male,23.9,91.2,High,1,0,1,1,0,,,,,0.38,1,0,6,1,0,1
+HLT003-ONC-TTE-001-00347,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,49,Male,26.5,37.7,Low,0,0,1,1,0,,,,,24.55,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00348,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,64,Male,29.9,68.5,High,0,0,1,1,0,,,,,35.53,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00349,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,38,Female,33.4,24.6,Low,0,0,1,1,0,,,,,21.71,1,0,3,0,0,1
+HLT003-ONC-TTE-001-00350,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,74,Male,30.4,38.3,Low,0,1,1,1,0,,,,,52.0,0,1,11,7,4,1
+HLT003-ONC-TTE-001-00351,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Female,35.8,82.3,High,0,0,1,1,0,,,,,11.63,0,1,6,2,1,1
+HLT003-ONC-TTE-001-00352,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,67,Male,27.9,50.3,Moderate,0,1,1,1,0,,,,,13.8,0,1,4,1,1,1
+HLT003-ONC-TTE-001-00353,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Male,26.6,70.1,High,1,0,1,1,0,,,,,6.64,0,1,3,1,1,1
+HLT003-ONC-TTE-001-00354,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,66,Female,44.2,59.3,Moderate,0,1,1,1,0,,,,,35.95,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00355,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,69,Male,30.8,53.1,Moderate,0,1,1,0,0,,,,,24.33,1,0,12,5,2,1
+HLT003-ONC-TTE-001-00356,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Female,24.3,79.5,High,0,0,1,0,1,,,,,52.0,0,1,20,12,5,1
+HLT003-ONC-TTE-001-00357,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,24.5,50.7,Moderate,0,0,1,1,0,,,,,12.65,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00358,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Female,23.0,22.9,Low,0,0,1,1,0,,,,,9.46,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00359,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,33.9,40.5,Low,0,0,1,1,0,,,,,17.12,1,0,12,3,1,1
+HLT003-ONC-TTE-001-00360,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,55,Male,26.4,64.9,High,0,0,1,1,0,,,,,8.05,1,0,20,11,4,1
+HLT003-ONC-TTE-001-00361,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,55,Female,29.2,62.1,High,0,0,1,1,0,,,,,38.33,1,0,20,13,7,1
+HLT003-ONC-TTE-001-00362,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Male,28.1,26.8,Low,0,0,1,1,0,,,,,5.88,1,0,6,2,0,1
+HLT003-ONC-TTE-001-00363,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,68,Male,32.7,42.0,Low,0,1,1,1,0,,,,,24.39,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00364,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,23.6,44.5,Low,1,0,1,1,0,,,,,11.85,0,1,5,2,1,1
+HLT003-ONC-TTE-001-00365,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,55,Female,22.3,48.4,Moderate,0,0,1,1,0,,,,,40.25,0,1,12,4,2,1
+HLT003-ONC-TTE-001-00366,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,74,Female,29.8,30.2,Low,1,1,1,1,0,,,,,39.53,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00367,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Female,32.0,43.7,Low,1,0,1,1,0,,,,,16.79,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00368,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,47,Female,30.4,41.9,Low,1,0,1,1,0,,,,,42.43,1,0,9,3,1,1
+HLT003-ONC-TTE-001-00369,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,23.8,68.9,High,0,0,1,1,0,,,,,29.67,1,0,4,3,2,1
+HLT003-ONC-TTE-001-00370,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,67,Female,32.4,69.6,High,1,1,1,0,1,,,,,0.74,1,0,15,5,2,1
+HLT003-ONC-TTE-001-00371,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,57,Male,24.2,52.4,Moderate,1,0,1,1,0,,,,,9.09,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00372,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,72,Female,25.5,47.9,Moderate,1,1,1,1,0,,,,,17.13,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00373,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Male,23.0,57.5,Moderate,0,1,1,1,0,,,,,5.6,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00374,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Female,36.0,40.3,Low,0,1,1,1,0,,,,,6.6,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00375,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,63,Male,32.2,34.4,Low,1,0,1,1,0,,,,,52.0,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00376,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,84,Male,32.0,38.1,Low,1,1,1,1,0,,,,,34.21,0,1,8,5,1,1
+HLT003-ONC-TTE-001-00377,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,54,Male,35.7,43.6,Low,0,0,1,1,0,,,,,13.74,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00378,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,32,Male,44.8,34.1,Low,1,0,1,1,0,,,,,23.71,1,0,10,3,1,1
+HLT003-ONC-TTE-001-00379,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,76,Male,18.6,57.9,Moderate,0,1,1,1,0,,,,,29.53,1,0,19,8,4,1
+HLT003-ONC-TTE-001-00380,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Female,24.2,68.1,High,0,0,1,1,0,,,,,21.67,0,1,4,2,2,1
+HLT003-ONC-TTE-001-00381,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,58,Male,24.9,26.4,Low,0,0,1,1,0,,,,,51.63,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00382,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,72,Female,23.6,55.5,Moderate,1,1,1,1,0,,,,,32.43,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00383,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,37,Male,22.3,51.0,Moderate,0,0,1,0,1,,,,,25.98,0,1,8,4,4,1
+HLT003-ONC-TTE-001-00384,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,41,Female,26.8,61.1,Moderate,1,0,1,1,0,,,,,11.74,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00385,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,37,Male,21.4,54.8,Moderate,0,0,1,1,0,,,,,15.05,0,1,16,7,3,1
+HLT003-ONC-TTE-001-00386,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,47,Female,30.4,28.8,Low,0,0,1,1,0,,,,,8.82,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00387,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,28.8,32.3,Low,0,0,1,1,0,,,,,7.53,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00388,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,63,Male,31.3,55.5,Moderate,0,0,1,1,0,,,,,1.47,1,0,4,3,1,1
+HLT003-ONC-TTE-001-00389,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,60,Female,31.4,73.5,High,1,0,1,1,0,,,,,15.74,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00390,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,40,Male,32.0,15.1,Low,0,0,1,1,0,,,,,13.75,0,1,6,2,0,1
+HLT003-ONC-TTE-001-00391,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,29,Male,26.3,61.2,Moderate,0,0,1,1,0,,,,,3.29,0,1,3,2,2,1
+HLT003-ONC-TTE-001-00392,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,57,Female,40.8,76.4,High,1,0,1,1,0,,,,,7.63,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00393,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Female,29.9,52.2,Moderate,0,0,1,1,0,,,,,52.0,0,1,2,2,2,1
+HLT003-ONC-TTE-001-00394,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Male,17.7,64.9,High,0,0,1,1,0,,,,,20.7,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00395,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,65,Male,22.7,42.3,Low,0,1,1,1,0,,,,,35.95,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00396,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,58,Female,18.4,52.9,Moderate,0,0,1,0,0,,,,,2.01,0,1,3,1,0,1
+HLT003-ONC-TTE-001-00397,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,66,Female,28.6,25.8,Low,0,1,1,1,0,,,,,13.75,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00398,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Female,27.8,12.8,Low,0,0,1,1,0,,,,,39.56,0,1,3,2,2,1
+HLT003-ONC-TTE-001-00399,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,63,Female,25.8,72.0,High,1,0,1,1,0,,,,,19.31,0,1,6,4,3,1
+HLT003-ONC-TTE-001-00400,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Female,40.2,37.3,Low,0,0,1,0,1,,,,,0.45,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00401,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Male,31.7,46.8,Moderate,1,0,1,1,0,,,,,24.61,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00402,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,32.7,30.0,Low,0,0,1,1,0,,,,,9.42,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00403,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Male,23.1,29.6,Low,0,1,1,1,0,,,,,34.15,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00404,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Female,22.7,51.9,Moderate,0,0,1,1,0,,,,,4.54,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00405,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,63,Male,28.7,41.9,Low,1,0,1,1,0,,,,,5.76,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00406,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,53,Female,29.5,61.8,High,1,0,1,1,0,,,,,3.53,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00407,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Female,17.7,63.1,High,0,0,1,0,1,,,,,26.5,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00408,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Male,27.5,60.8,Moderate,1,1,1,1,0,,,,,6.13,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00409,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,33,Female,28.6,59.3,Moderate,1,0,1,1,0,,,,,3.32,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00410,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,41,Male,27.3,83.4,High,0,0,1,1,0,,,,,52.0,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00411,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,39,Female,23.8,35.8,Low,0,0,1,1,0,,,,,16.76,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00412,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,28,Male,25.4,54.0,Moderate,0,0,1,1,0,,,,,37.3,0,1,6,2,2,1
+HLT003-ONC-TTE-001-00413,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Male,27.5,75.4,High,0,0,1,1,0,,,,,16.67,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00414,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,65,Male,29.0,77.8,High,0,1,1,1,0,,,,,39.02,1,0,5,3,1,1
+HLT003-ONC-TTE-001-00415,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,32.0,29.4,Low,1,0,1,1,0,,,,,8.99,1,0,11,7,5,1
+HLT003-ONC-TTE-001-00416,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Male,34.8,49.4,Moderate,0,0,1,1,0,,,,,2.34,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00417,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Female,26.8,79.4,High,0,1,1,0,0,,,,,28.43,1,0,7,3,2,1
+HLT003-ONC-TTE-001-00418,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,72,Female,25.9,64.1,High,0,1,1,1,0,,,,,21.63,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00419,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,31.0,58.5,Moderate,0,0,1,1,0,,,,,1.61,1,0,7,4,1,1
+HLT003-ONC-TTE-001-00420,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,73,Male,32.0,51.1,Moderate,0,1,1,1,0,,,,,18.97,1,0,13,7,3,1
+HLT003-ONC-TTE-001-00421,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,58,Male,26.0,48.1,Moderate,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00422,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,33.1,60.2,Moderate,0,0,1,1,0,,,,,14.81,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00423,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,49,Female,34.2,50.5,Moderate,0,0,1,1,0,,,,,9.69,1,0,8,4,2,1
+HLT003-ONC-TTE-001-00424,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,39,Female,36.0,54.2,Moderate,1,0,1,1,0,,,,,20.2,0,1,11,5,3,1
+HLT003-ONC-TTE-001-00425,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,38.8,56.4,Moderate,1,0,1,0,0,,,,,17.6,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00426,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,52,Female,23.5,42.8,Low,0,0,1,1,0,,,,,21.09,1,0,3,1,1,1
+HLT003-ONC-TTE-001-00427,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,66,Male,28.6,64.6,High,1,1,1,1,0,,,,,52.0,0,1,2,1,0,1
+HLT003-ONC-TTE-001-00428,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,77,Male,28.6,100.0,High,0,1,1,1,0,,,,,16.58,1,0,5,2,0,1
+HLT003-ONC-TTE-001-00429,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,40,Male,27.9,23.0,Low,0,0,1,1,0,,,,,52.0,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00430,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Male,24.7,60.8,Moderate,0,0,1,1,0,,,,,18.41,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00431,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,44,Female,19.9,41.3,Low,1,0,1,1,0,,,,,52.0,0,1,4,0,0,1
+HLT003-ONC-TTE-001-00432,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,29.0,65.4,High,0,0,1,1,0,,,,,14.31,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00433,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Male,24.0,55.8,Moderate,0,0,1,1,0,,,,,2.85,1,0,8,2,1,1
+HLT003-ONC-TTE-001-00434,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,35,Female,29.0,68.7,High,1,0,1,0,1,,,,,3.19,1,0,2,1,1,1
+HLT003-ONC-TTE-001-00435,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,68,Female,23.9,76.2,High,1,1,1,1,0,,,,,16.42,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00436,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,49,Female,22.1,58.5,Moderate,1,0,1,1,0,,,,,27.46,0,1,6,4,1,1
+HLT003-ONC-TTE-001-00437,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Female,29.9,75.4,High,1,0,1,1,0,,,,,16.04,1,0,11,3,1,1
+HLT003-ONC-TTE-001-00438,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,29.4,12.8,Low,1,0,1,0,0,,,,,4.21,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00439,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,49,Female,31.9,83.6,High,0,0,1,0,0,,,,,2.93,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00440,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Male,41.2,61.8,Moderate,0,0,1,1,0,,,,,33.57,1,0,4,1,1,1
+HLT003-ONC-TTE-001-00441,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Female,30.1,74.4,High,1,0,1,1,0,,,,,5.23,1,0,8,4,1,1
+HLT003-ONC-TTE-001-00442,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,60,Male,31.3,33.0,Low,1,0,1,1,0,,,,,17.37,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00443,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,61,Female,22.3,40.0,Low,1,0,1,0,1,,,,,45.48,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00444,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,72,Male,21.0,57.6,Moderate,0,1,1,1,0,,,,,1.8,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00445,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,52,Male,37.7,54.7,Moderate,1,0,1,1,0,,,,,24.74,1,0,7,3,0,1
+HLT003-ONC-TTE-001-00446,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,39,Female,23.1,60.1,Moderate,0,0,1,1,0,,,,,6.96,0,1,20,5,3,1
+HLT003-ONC-TTE-001-00447,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,69,Female,22.4,74.5,High,1,1,1,1,0,,,,,6.11,1,0,10,6,3,1
+HLT003-ONC-TTE-001-00448,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,53,Male,28.3,23.2,Low,1,0,1,0,1,,,,,52.0,0,1,18,8,3,1
+HLT003-ONC-TTE-001-00449,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Female,28.0,72.5,High,0,1,1,1,0,,,,,7.4,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00450,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Female,23.3,55.1,Moderate,1,0,1,1,0,,,,,11.34,1,0,6,2,1,1
+HLT003-ONC-TTE-001-00451,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,55,Male,26.7,51.3,Moderate,1,0,1,1,0,,,,,13.21,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00452,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Female,35.6,28.5,Low,1,0,1,1,0,,,,,22.52,1,0,6,5,1,1
+HLT003-ONC-TTE-001-00453,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,80,Male,23.8,64.1,High,0,1,1,0,1,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00454,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,81,Female,20.4,11.5,Low,0,1,1,1,0,,,,,19.96,0,1,3,0,0,1
+HLT003-ONC-TTE-001-00455,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,57,Male,34.0,66.7,High,0,0,1,0,1,,,,,14.58,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00456,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Male,31.4,28.1,Low,0,0,1,0,0,,,,,50.11,1,0,8,3,1,1
+HLT003-ONC-TTE-001-00457,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,69,Female,24.9,56.0,Moderate,1,1,1,1,0,,,,,13.67,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00458,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Female,19.3,52.9,Moderate,0,0,1,1,0,,,,,52.0,0,1,12,6,4,1
+HLT003-ONC-TTE-001-00459,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Female,24.2,76.1,High,1,0,1,1,0,,,,,16.72,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00460,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,28.2,51.8,Moderate,0,0,1,1,0,,,,,29.61,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00461,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Female,35.3,42.5,Low,0,0,1,1,0,,,,,25.63,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00462,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,46,Female,22.5,45.9,Moderate,0,0,1,1,0,,,,,21.66,1,0,9,3,3,1
+HLT003-ONC-TTE-001-00463,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,37,Female,28.0,77.9,High,0,0,1,1,0,,,,,52.0,0,1,11,5,2,1
+HLT003-ONC-TTE-001-00464,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,32,Male,32.4,64.7,High,1,0,1,0,1,,,,,52.0,0,1,6,1,1,1
+HLT003-ONC-TTE-001-00465,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,43,Male,16.0,48.1,Moderate,0,0,1,0,1,,,,,9.4,1,0,4,2,2,1
+HLT003-ONC-TTE-001-00466,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,51,Male,34.5,50.7,Moderate,0,0,1,1,0,,,,,51.47,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00467,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,53,Female,21.6,26.8,Low,0,0,1,1,0,,,,,52.0,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00468,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,80,Male,30.4,62.0,High,0,1,1,1,0,,,,,9.02,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00469,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Male,29.9,23.3,Low,1,1,1,1,0,,,,,1.57,1,0,6,1,0,1
+HLT003-ONC-TTE-001-00470,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,45,Female,34.8,68.5,High,0,0,1,1,0,,,,,52.0,0,1,4,2,2,1
+HLT003-ONC-TTE-001-00471,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Male,31.7,57.3,Moderate,0,0,1,1,0,,,,,9.57,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00472,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Male,16.0,98.0,High,0,0,1,1,0,,,,,28.86,0,1,10,3,1,1
+HLT003-ONC-TTE-001-00473,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Female,23.9,35.2,Low,1,0,1,1,0,,,,,21.66,1,0,5,3,3,1
+HLT003-ONC-TTE-001-00474,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,29.3,53.2,Moderate,0,0,1,1,0,,,,,4.62,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00475,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,64,Male,27.4,87.4,High,0,0,1,1,0,,,,,31.0,1,0,4,1,1,1
+HLT003-ONC-TTE-001-00476,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,52,Male,31.3,76.4,High,0,0,1,1,0,,,,,14.64,0,1,4,2,0,1
+HLT003-ONC-TTE-001-00477,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,69,Male,33.1,42.5,Low,1,1,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00478,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,43,Female,32.0,59.0,Moderate,1,0,1,1,0,,,,,16.01,1,0,3,2,2,1
+HLT003-ONC-TTE-001-00479,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,57,Female,27.3,55.0,Moderate,0,0,1,1,0,,,,,0.53,1,0,4,3,1,1
+HLT003-ONC-TTE-001-00480,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,85,Male,17.8,60.1,Moderate,1,1,1,1,0,,,,,0.66,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00481,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,25.9,42.4,Low,0,0,1,1,0,,,,,16.02,1,0,11,5,2,1
+HLT003-ONC-TTE-001-00482,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,74,Male,30.9,53.4,Moderate,0,1,1,0,1,,,,,29.85,1,0,4,2,2,1
+HLT003-ONC-TTE-001-00483,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Male,22.2,26.2,Low,1,0,1,1,0,,,,,16.91,1,0,3,2,2,1
+HLT003-ONC-TTE-001-00484,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,63,Female,32.2,57.4,Moderate,1,0,1,1,0,,,,,12.89,0,1,7,3,3,1
+HLT003-ONC-TTE-001-00485,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Male,33.8,63.1,High,0,0,1,1,0,,,,,10.76,1,0,7,1,1,1
+HLT003-ONC-TTE-001-00486,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,54,Male,29.2,50.9,Moderate,1,0,1,1,0,,,,,30.82,1,0,10,6,1,1
+HLT003-ONC-TTE-001-00487,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,47,Male,16.0,25.9,Low,0,0,1,1,0,,,,,33.5,1,0,15,8,4,1
+HLT003-ONC-TTE-001-00488,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Female,21.1,72.8,High,0,0,1,1,0,,,,,8.53,1,0,3,3,3,1
+HLT003-ONC-TTE-001-00489,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Female,39.4,61.6,Moderate,0,0,1,1,0,,,,,15.54,1,0,2,2,2,1
+HLT003-ONC-TTE-001-00490,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,64,Female,25.3,41.9,Low,0,0,1,1,0,,,,,33.65,1,0,4,1,0,1
+HLT003-ONC-TTE-001-00491,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Male,17.0,49.9,Moderate,0,1,1,1,0,,,,,28.1,1,0,7,2,2,1
+HLT003-ONC-TTE-001-00492,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Male,35.7,28.0,Low,0,0,1,1,0,,,,,3.53,1,0,7,3,1,1
+HLT003-ONC-TTE-001-00493,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Female,28.6,36.5,Low,1,0,1,1,0,,,,,24.51,1,0,12,2,2,1
+HLT003-ONC-TTE-001-00494,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Male,34.9,45.3,Low,0,0,1,1,0,,,,,52.0,0,1,3,1,1,1
+HLT003-ONC-TTE-001-00495,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,53,Female,30.1,77.1,High,0,0,1,1,0,,,,,12.52,0,1,4,4,2,1
+HLT003-ONC-TTE-001-00496,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,68,Female,31.2,43.5,Low,0,1,1,1,0,,,,,11.8,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00497,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,35,Male,30.6,66.5,High,0,0,1,1,0,,,,,52.0,0,1,9,2,0,1
+HLT003-ONC-TTE-001-00498,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,52,Female,32.5,45.3,Low,1,0,1,1,0,,,,,29.43,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00499,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,33,Male,41.7,59.5,Moderate,1,0,1,1,0,,,,,13.2,0,1,4,0,0,1
+HLT003-ONC-TTE-001-00500,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,39,Male,34.1,52.5,Moderate,1,0,1,1,0,,,,,21.97,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00501,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,73,Female,19.3,70.7,High,1,1,1,1,0,,,,,1.08,0,1,20,10,4,1
+HLT003-ONC-TTE-001-00502,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Male,31.1,45.4,Low,0,1,1,1,0,,,,,31.3,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00503,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,48,Female,35.1,26.7,Low,1,0,1,0,0,,,,,37.2,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00504,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,38,Female,35.5,30.1,Low,0,0,1,1,0,,,,,52.0,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00505,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,21,Female,26.0,45.4,Low,1,0,1,1,0,,,,,0.32,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00506,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Female,35.3,32.5,Low,1,0,1,1,0,,,,,0.68,1,0,5,1,1,1
+HLT003-ONC-TTE-001-00507,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,85,Male,33.9,62.4,High,0,1,1,1,0,,,,,44.32,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00508,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,62,Male,43.4,46.6,Moderate,1,0,1,1,0,,,,,4.03,1,0,3,1,1,1
+HLT003-ONC-TTE-001-00509,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Female,24.1,97.7,High,0,0,1,1,0,,,,,16.51,1,0,8,4,3,1
+HLT003-ONC-TTE-001-00510,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,62,Female,25.6,23.7,Low,0,0,1,1,0,,,,,7.06,1,0,6,2,0,1
+HLT003-ONC-TTE-001-00511,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,38,Male,26.7,58.7,Moderate,0,0,1,0,0,,,,,39.36,0,1,16,6,5,1
+HLT003-ONC-TTE-001-00512,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,25.7,34.7,Low,1,0,1,1,0,,,,,1.06,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00513,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,58,Male,23.3,46.1,Moderate,0,0,1,1,0,,,,,3.77,0,1,5,2,2,1
+HLT003-ONC-TTE-001-00514,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Male,16.0,57.5,Moderate,1,0,1,1,0,,,,,38.9,1,0,8,2,0,1
+HLT003-ONC-TTE-001-00515,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Female,26.0,13.1,Low,0,1,1,1,0,,,,,5.48,1,0,8,2,2,1
+HLT003-ONC-TTE-001-00516,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Male,30.6,59.3,Moderate,0,0,1,1,0,,,,,23.15,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00517,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,65,Female,25.6,89.3,High,1,1,1,1,0,,,,,1.77,1,0,20,7,3,1
+HLT003-ONC-TTE-001-00518,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,48,Female,39.7,46.8,Moderate,1,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00519,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,67,Female,28.6,59.7,Moderate,1,1,1,1,0,,,,,5.93,1,0,5,1,0,1
+HLT003-ONC-TTE-001-00520,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,76,Male,36.0,73.4,High,1,1,1,1,0,,,,,17.05,1,0,10,5,3,1
+HLT003-ONC-TTE-001-00521,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,45,Male,30.0,52.0,Moderate,0,0,1,1,0,,,,,23.08,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00522,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,46,Female,33.3,44.5,Low,0,0,1,1,0,,,,,14.55,1,0,3,1,0,1
+HLT003-ONC-TTE-001-00523,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,73,Female,30.1,14.0,Low,0,1,1,0,1,,,,,50.89,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00524,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Male,36.4,66.5,High,1,0,1,1,0,,,,,7.31,1,0,1,1,0,1
+HLT003-ONC-TTE-001-00525,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,73,Female,28.8,53.0,Moderate,0,1,1,1,0,,,,,1.13,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00526,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,51,Male,31.4,36.8,Low,1,0,1,1,0,,,,,46.7,0,1,3,2,1,1
+HLT003-ONC-TTE-001-00527,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,74,Female,30.6,57.3,Moderate,0,1,1,1,0,,,,,8.07,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00528,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,58,Male,26.8,44.5,Low,1,0,1,1,0,,,,,11.79,1,0,15,5,3,1
+HLT003-ONC-TTE-001-00529,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Male,30.8,45.5,Moderate,1,0,1,1,0,,,,,0.65,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00530,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,75,Female,41.5,65.9,High,0,1,1,1,0,,,,,52.0,0,1,10,6,6,1
+HLT003-ONC-TTE-001-00531,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,52,Male,26.9,30.9,Low,1,0,1,1,0,,,,,32.13,1,0,9,3,1,1
+HLT003-ONC-TTE-001-00532,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,45,Male,30.9,73.9,High,0,0,1,1,0,,,,,15.88,0,1,1,1,1,1
+HLT003-ONC-TTE-001-00533,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,51,Male,35.8,29.8,Low,0,0,1,1,0,,,,,26.14,1,0,2,2,0,1
+HLT003-ONC-TTE-001-00534,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,62,Male,35.1,43.1,Low,1,0,1,1,0,,,,,11.46,1,0,12,5,3,1
+HLT003-ONC-TTE-001-00535,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,38,Female,28.6,89.6,High,0,0,1,0,1,,,,,52.0,0,1,20,9,4,1
+HLT003-ONC-TTE-001-00536,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,64,Male,16.0,75.3,High,0,0,1,1,0,,,,,52.0,0,1,16,9,6,1
+HLT003-ONC-TTE-001-00537,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,50,Female,31.5,56.8,Moderate,0,0,1,1,0,,,,,35.81,1,0,20,9,5,1
+HLT003-ONC-TTE-001-00538,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,70,Female,16.0,38.1,Low,0,1,1,1,0,,,,,24.33,0,1,5,3,1,1
+HLT003-ONC-TTE-001-00539,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,28,Male,37.0,45.5,Low,0,0,1,1,0,,,,,1.53,1,0,1,1,1,1
+HLT003-ONC-TTE-001-00540,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,47,Male,29.5,56.3,Moderate,0,0,1,1,0,,,,,46.74,0,1,3,1,1,1
+HLT003-ONC-TTE-001-00541,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,36,Female,34.3,55.7,Moderate,0,0,1,0,0,,,,,11.39,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00542,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,47,Female,23.3,53.4,Moderate,0,0,1,0,0,,,,,33.34,1,0,3,1,1,1
+HLT003-ONC-TTE-001-00543,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,59,Female,19.5,54.4,Moderate,1,0,1,1,0,,,,,16.31,1,0,5,1,1,1
+HLT003-ONC-TTE-001-00544,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,54,Female,30.0,51.1,Moderate,1,0,1,1,0,,,,,3.57,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00545,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,53,Male,28.3,29.0,Low,0,0,1,1,0,,,,,28.22,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00546,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Male,25.6,45.7,Moderate,1,0,1,1,0,,,,,3.33,0,1,2,0,0,1
+HLT003-ONC-TTE-001-00547,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,29.0,71.5,High,1,0,1,1,0,,,,,3.79,0,1,13,2,2,1
+HLT003-ONC-TTE-001-00548,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,44.6,30.4,Low,1,0,1,1,0,,,,,5.28,1,0,7,2,2,1
+HLT003-ONC-TTE-001-00549,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,65,Female,33.3,51.6,Moderate,0,1,1,1,0,,,,,4.18,1,0,20,12,7,1
+HLT003-ONC-TTE-001-00550,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,64,Male,34.6,40.2,Low,1,0,1,1,0,,,,,32.64,1,0,2,2,1,1
+HLT003-ONC-TTE-001-00551,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,61,Female,33.4,57.0,Moderate,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00552,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,63,Male,37.1,48.0,Moderate,0,0,1,1,0,,,,,41.05,1,0,3,3,1,1
+HLT003-ONC-TTE-001-00553,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,60,Male,27.4,81.6,High,0,0,1,1,0,,,,,8.16,0,1,4,1,1,1
+HLT003-ONC-TTE-001-00554,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,81,Male,16.6,64.1,High,1,1,1,1,0,,,,,1.87,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00555,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Male,27.4,31.4,Low,0,0,1,0,1,,,,,21.21,1,0,3,2,1,1
+HLT003-ONC-TTE-001-00556,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,53,Female,33.2,67.1,High,0,0,1,1,0,,,,,52.0,0,1,20,7,4,1
+HLT003-ONC-TTE-001-00557,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,47,Male,22.9,41.1,Low,0,0,1,1,0,,,,,29.54,0,1,4,3,2,1
+HLT003-ONC-TTE-001-00558,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,27.5,44.6,Low,0,0,1,1,0,,,,,9.86,0,1,4,2,1,1
+HLT003-ONC-TTE-001-00559,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Male,24.5,60.6,Moderate,1,0,1,1,0,,,,,23.19,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00560,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,46,Male,37.2,46.1,Moderate,0,0,1,1,0,,,,,49.85,1,0,13,7,4,1
+HLT003-ONC-TTE-001-00561,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,56,Female,32.8,71.1,High,1,0,1,1,0,,,,,12.8,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00562,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,61,Male,32.3,41.1,Low,0,0,1,1,0,,,,,19.99,1,0,7,4,2,1
+HLT003-ONC-TTE-001-00563,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,57,Female,32.1,43.9,Low,0,0,1,1,0,,,,,1.94,0,1,1,1,0,1
+HLT003-ONC-TTE-001-00564,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,47,Male,28.3,43.2,Low,1,0,1,0,0,,,,,2.37,0,1,2,1,1,1
+HLT003-ONC-TTE-001-00565,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,67,Female,29.6,44.8,Low,0,1,1,1,0,,,,,12.39,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00566,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,65,Male,21.6,74.8,High,1,1,1,1,0,,,,,16.94,0,1,7,3,1,1
+HLT003-ONC-TTE-001-00567,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,55,Male,16.0,66.3,High,0,0,1,1,0,,,,,34.65,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00568,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,49,Female,29.4,85.8,High,0,0,1,1,0,,,,,30.88,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00569,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,63,Female,30.4,95.8,High,1,0,1,1,0,,,,,4.16,0,1,10,5,2,1
+HLT003-ONC-TTE-001-00570,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,35.5,36.4,Low,1,0,1,1,0,,,,,0.52,1,0,4,2,2,1
+HLT003-ONC-TTE-001-00571,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,39,Male,37.6,56.3,Moderate,0,0,1,1,0,,,,,29.16,0,1,9,2,1,1
+HLT003-ONC-TTE-001-00572,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,56,Male,37.6,33.8,Low,1,0,1,1,0,,,,,2.45,1,0,5,1,1,1
+HLT003-ONC-TTE-001-00573,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,60,Female,22.7,41.0,Low,0,0,1,1,0,,,,,5.25,1,0,10,4,3,1
+HLT003-ONC-TTE-001-00574,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Male,26.5,43.7,Low,0,0,1,1,0,,,,,13.63,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00575,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Female,31.3,36.0,Low,0,0,1,1,0,,,,,42.1,1,0,6,2,1,1
+HLT003-ONC-TTE-001-00576,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,39,Female,43.2,36.1,Low,1,0,1,1,0,,,,,27.51,0,1,2,1,0,1
+HLT003-ONC-TTE-001-00577,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,73,Female,37.1,52.4,Moderate,0,1,1,0,1,,,,,2.85,1,0,0,0,0,0
+HLT003-ONC-TTE-001-00578,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,71,Female,35.0,33.1,Low,0,1,1,0,0,,,,,1.18,1,0,3,3,3,1
+HLT003-ONC-TTE-001-00579,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Female,26.3,70.2,High,1,0,1,1,0,,,,,23.16,1,0,4,2,2,1
+HLT003-ONC-TTE-001-00580,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,61,Male,23.4,38.5,Low,1,0,1,1,0,,,,,20.75,1,0,3,1,0,1
+HLT003-ONC-TTE-001-00581,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,28,Male,33.1,100.0,High,1,0,1,1,0,,,,,6.8,0,1,10,4,2,1
+HLT003-ONC-TTE-001-00582,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,43,Female,22.1,46.9,Moderate,0,0,1,1,0,,,,,25.27,1,0,4,3,3,1
+HLT003-ONC-TTE-001-00583,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,53,Male,27.1,56.3,Moderate,0,0,1,1,0,,,,,52.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00584,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,44,Male,27.8,31.7,Low,0,0,1,1,0,,,,,1.56,1,0,3,1,1,1
+HLT003-ONC-TTE-001-00585,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,65,Male,37.7,85.7,High,0,1,1,0,1,,,,,7.77,0,1,3,2,1,1
+HLT003-ONC-TTE-001-00586,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,80,Female,26.4,75.2,High,1,1,1,1,0,,,,,21.99,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00587,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Female,16.0,60.3,Moderate,1,0,1,1,0,,,,,0.7,1,0,2,1,0,1
+HLT003-ONC-TTE-001-00588,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,46,Female,31.4,30.8,Low,1,0,1,1,0,,,,,1.99,1,0,1,0,0,1
+HLT003-ONC-TTE-001-00589,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,59,Male,24.4,58.8,Moderate,0,0,1,1,0,,,,,10.13,1,0,4,3,1,1
+HLT003-ONC-TTE-001-00590,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,76,Male,28.7,34.8,Low,0,1,1,0,1,,,,,6.38,1,0,20,14,9,1
+HLT003-ONC-TTE-001-00591,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,42,Female,28.0,81.3,High,0,0,1,1,0,,,,,1.11,1,0,7,4,2,1
+HLT003-ONC-TTE-001-00592,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,59,Male,26.9,69.6,High,0,0,1,0,0,,,,,4.0,0,1,0,0,0,0
+HLT003-ONC-TTE-001-00593,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,78,Female,33.1,56.7,Moderate,1,1,1,1,0,,,,,30.95,1,0,2,0,0,1
+HLT003-ONC-TTE-001-00594,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,37,Female,19.6,11.1,Low,1,0,1,0,1,,,,,52.0,0,1,13,8,6,1
+HLT003-ONC-TTE-001-00595,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,41,Male,25.5,37.3,Low,1,0,1,1,0,,,,,4.71,1,0,16,5,3,1
+HLT003-ONC-TTE-001-00596,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.3,51,Male,32.5,67.4,High,0,0,1,1,0,,,,,26.92,0,1,16,10,3,1
+HLT003-ONC-TTE-001-00597,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,50,Male,24.9,76.8,High,0,0,1,1,0,,,,,52.0,0,1,1,0,0,1
+HLT003-ONC-TTE-001-00598,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,66,Female,19.2,75.0,High,0,1,1,1,0,,,,,11.12,1,0,8,6,2,1
+HLT003-ONC-TTE-001-00599,HLT003-ONC-TTE-001,Oncology,II,1,Targeted Therapy,0.375,59,Female,32.4,26.3,Low,1,0,1,1,0,,,,,35.66,0,1,4,1,1,1
+HLT003-ONC-TTE-001-00600,HLT003-ONC-TTE-001,Oncology,II,0,SoC Chemotherapy,0.0,35,Male,35.0,60.4,Moderate,1,0,1,1,0,,,,,28.31,0,1,1,1,0,1

power_sweep_results.csv ADDED Viewed

	@@ -0,0 +1,8 @@

+n_participants,power,n_simulations,alpha,endpoint_type
+200,0.28,50,0.05,CONTINUOUS
+400,0.58,50,0.05,CONTINUOUS
+600,0.7,50,0.05,CONTINUOUS
+800,0.74,50,0.05,CONTINUOUS
+1200,0.92,50,0.05,CONTINUOUS
+1800,1.0,50,0.05,CONTINUOUS
+2500,1.0,50,0.05,CONTINUOUS

rheumatology_acr20_config.json ADDED Viewed

	@@ -0,0 +1,85 @@

+{
+  "trial_id": "HLT003-RHEUM-BIN-001",
+  "trial_name": "Phase III RCT \u2014 Rheumatoid Arthritis ACR20 Response",
+  "sponsor": "XpertSystems Pharma LLC",
+  "n_participants": 800,
+  "trial_phase": "III",
+  "blinding": "DOUBLE",
+  "randomization": "STRATIFIED",
+  "n_sites": 25,
+  "arms": [
+    {
+      "arm_id": 0,
+      "label": "Placebo",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.0,
+      "ae_multiplier": 1.0
+    },
+    {
+      "arm_id": 1,
+      "label": "Biologic 200mg",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.3,
+      "ae_multiplier": 1.5
+    },
+    {
+      "arm_id": 2,
+      "label": "Biologic 400mg",
+      "randomization_weight": 1,
+      "treatment_effect_cohens_d": 0.6,
+      "ae_multiplier": 2.0
+    }
+  ],
+  "therapeutic_area": "Rheumatology",
+  "endpoint_type": "BINARY",
+  "endpoint_name": "ACR20 Response at Week 24",
+  "endpoint_unit": "%",
+  "binary_baseline_response_rate": 0.22,
+  "binary_odds_ratios": [
+    1.0,
+    2.5,
+    4.0
+  ],
+  "visit_schedule": [
+    -2,
+    0,
+    1,
+    2,
+    4,
+    8,
+    12,
+    16,
+    20,
+    24
+  ],
+  "dropout_mcar_rate": 0.04,
+  "dropout_mar_baseline_logit": -3.5,
+  "dropout_mar_severity_coef": 0.025,
+  "dropout_mar_age_coef": 0.015,
+  "dropout_mar_arm_coef": 0.4,
+  "dropout_mnar_fraction": 0.15,
+  "ae_base_rate_per_patient": 3.2,
+  "ae_active_arm_increment": 1.5,
+  "ae_grade_probs_placebo": [
+    0.45,
+    0.32,
+    0.16,
+    0.05,
+    0.02
+  ],
+  "ae_grade_probs_active": [
+    0.38,
+    0.3,
+    0.2,
+    0.08,
+    0.04
+  ],
+  "subgroups": {
+    "biomarker_positive_fraction": 0.42,
+    "biomarker_treatment_interaction": 0.2,
+    "elderly_fraction": 0.28,
+    "elderly_ae_multiplier": 1.3
+  },
+  "output_filename": "rheumatology_acr20_trial.csv",
+  "seed": 42
+}

rheumatology_acr20_trial.csv ADDED Viewed

The diff for this file is too large to render. See raw diff

simulation_audit_log.txt ADDED Viewed

	@@ -0,0 +1,48 @@

+======================================================================
+HLT-003 SIMULATION ENGINE — AUDIT LOG
+XpertSystems.ai · Synthetic Data Factory
+======================================================================
+Generated:          2026-05-17 13:32:31 UTC
+Engine Version:     1.0
+Trial ID:           HLT003-ONC-TTE-001
+Therapeutic Area:   Oncology
+Trial Phase:        II
+Endpoint Type:      TTE
+Seed:               42
+N Participants:     600
+N Arms:             2
+Elapsed:            0.05s
+ARM CONFIGURATION
+----------------------------------------
+  Arm 0: SoC Chemotherapy     | d=0.00 | AE mult=1.0
+  Arm 1: Targeted Therapy     | d=0.30 | AE mult=1.3
+RESULTS SUMMARY
+----------------------------------------
+  Arm 0 [SoC Chemotherapy]:
+    n = 301
+    Dropout = 8.6%
+    Events = 180 (59.8%)
+    AEs (mean) = 4.7
+    Grade 3+ AEs (mean) = 1.9
+    SAEs (mean) = 1.00
+  Arm 1 [Targeted Therapy]:
+    n = 299
+    Dropout = 8.4%
+    Events = 160 (53.5%)
+    AEs (mean) = 6.1
+    Grade 3+ AEs (mean) = 2.9
+    SAEs (mean) = 1.64
+REPRODUCIBILITY
+----------------------------------------
+  Re-run command: python hlt003_simulation_engine.py --seed 42
+  All outputs are deterministic with this seed.
+OUTPUT FILES
+----------------------------------------
+  /home/claude/hlt003_work/hlt003_sample/oncology_pfs_trial.csv
+  trial_config_schema.json
+  simulation_audit_log.txt
+======================================================================

trial_config_schema.json ADDED Viewed

	@@ -0,0 +1,90 @@

+{
+  "trial_id": {
+    "type": "string",
+    "description": "Unique trial identifier string"
+  },
+  "n_participants": {
+    "type": "integer",
+    "description": "Total randomized participants (100\u201350000)",
+    "range": [
+      100,
+      50000
+    ]
+  },
+  "trial_phase": {
+    "type": "string",
+    "description": "I | II | III | IV"
+  },
+  "blinding": {
+    "type": "string",
+    "description": "OPEN | SINGLE | DOUBLE"
+  },
+  "randomization": {
+    "type": "string",
+    "description": "SIMPLE | BLOCK | STRATIFIED | MINIMIZATION"
+  },
+  "n_sites": {
+    "type": "integer",
+    "description": "Number of investigator sites (5\u2013200)"
+  },
+  "arms": {
+    "type": "array",
+    "description": "List of arm objects: {arm_id, label, randomization_weight, treatment_effect_cohens_d, ae_multiplier}"
+  },
+  "therapeutic_area": {
+    "type": "string",
+    "description": "Cardiology | Oncology | Neurology | Metabolic | Respiratory | Psychiatry | Rheumatology | Infectious Disease | Rare Disease | Ophthalmology | Dermatology | GI"
+  },
+  "endpoint_type": {
+    "type": "string",
+    "description": "CONTINUOUS | BINARY | TTE"
+  },
+  "endpoint_name": {
+    "type": "string",
+    "description": "Human-readable endpoint label"
+  },
+  "baseline_mean": {
+    "type": "float",
+    "description": "Mean baseline endpoint value (CONTINUOUS only)"
+  },
+  "baseline_sd": {
+    "type": "float",
+    "description": "SD of baseline endpoint (CONTINUOUS only)"
+  },
+  "placebo_change_mean": {
+    "type": "float",
+    "description": "Mean CFB for placebo arm at primary visit (CONTINUOUS only)"
+  },
+  "binary_baseline_response_rate": {
+    "type": "float",
+    "description": "Placebo response probability (BINARY only, 0\u20131)"
+  },
+  "binary_odds_ratios": {
+    "type": "array",
+    "description": "Odds ratios vs placebo per arm (BINARY only)"
+  },
+  "tte_median_placebo_weeks": {
+    "type": "float",
+    "description": "Median survival weeks in placebo (TTE only)"
+  },
+  "tte_hazard_ratios": {
+    "type": "array",
+    "description": "Hazard ratios vs placebo per arm (TTE only, <1 = benefit)"
+  },
+  "dropout_mcar_rate": {
+    "type": "float",
+    "description": "Base MCAR dropout probability per visit (0\u20130.05)"
+  },
+  "dropout_mar_arm_coef": {
+    "type": "float",
+    "description": "Logit coefficient for arm index in MAR dropout model"
+  },
+  "ae_base_rate_per_patient": {
+    "type": "float",
+    "description": "Expected AEs per placebo patient"
+  },
+  "ae_active_arm_increment": {
+    "type": "float",
+    "description": "Additional AEs per active arm step above placebo"
+  }
+}